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Type 1 diabetes (T1D) is an immune-mediated disease that affects ~0.7% of children in 
Finland. Its incidence in Finland is the highest worldwide. The disease starts with an 
asymptomatic period with an ongoing immune-mediated destruction of β-cells and 
detectable autoantibodies against islet antigens. This process leads to hyperglycemia and 
eventually clinical symptoms when insulin secretion is no longer sufficient. The 
proposed etiology of T1D is both genetic and environmental. Many of these etiological 
factors are shared between other autoimmune diseases (AIDs) and, accordingly, these 
diseases co-occur in patients with T1D and their relatives. This thesis aims at 
characterizing the frequency of additional autoimmunity in Finnish children under the 
age of 15 years with newly diagnosed T1D and in their extended family members, as 
well as characterizing the effects of this additional autoimmunity on clinical, metabolic, 
and genetic markers, and T1D autoantibodies. 
Subjects and methods 
The subjects for this thesis are participants of the Finnish Pediatric Diabetes Register 
and Sample Repository. This is a nationwide register inviting participation of all newly 
diagnosed patients with T1D from all pediatric units in Finland. Over 90% of the patients 
and families participate in the Register. With the help of their medical team, the 
participating families fill in questionnaires on the clinical parameters, family 
characteristics and diabetes and other diseases of the index child and family members. 
Data on these diseases is collected with open questions, but examples such as celiac 
disease (CD), thyroid dysfunction, adrenal dysfunction, rheumatoid arthritis, multiple 
sclerosis, pernicious anemia and systemic lupus erythematosus are given. 
Approximately 70% also give blood samples for the Sample Repository to study 
childhood diabetes and its comorbidities. This thesis analyses data from the time of 
diagnosis on 2245 children diagnosed with T1D since the beginning of the Register in 
January 2002 up to November 2009. The mean age at diagnosis of T1D for the study 
population is 7.9 years and the majority are boys (57.1%). For a subset of the cases, 












Additional AIDs were reported by 1.6% children at diagnosis and by 3.2% after a 
median eight years of follow-up. After follow-up, CD was reported by 1.5%, 
autoimmune thyroid disease by 1.3%, rheumatoid disease by 0.3% and other AIDs by 
0.2% of the 2245 children. More than 20% of the families reported first- and/or second-
degree relatives with T1D, and over a third, relatives with other AIDs. Fathers were more 
often affected by T1D compared to mothers (6 vs. 3%), whereas mothers were more 
often affected by other AIDs (10 vs. 4%). Girls had more often T1D affected paternal 
and boys T1D affected maternal second-degree relatives. At T1D diagnosis, 5% of the 
index children and 3% of their relatives had tissue transglutaminase autoantibodies (anti-
tTG) related to CD. Transient anti-tTG not developing to CD seemed more common 
among children with T1D than among their relatives. The HLA-DR3-DQ2 haplotype 
was associated with CD autoimmunity and the HLA-DR4-DQ8 haplotype with familial 
T1D. The children with AIDs other than CD had neutral or protective T1D related HLA 
genotypes conspicuously often. Also, non-HLA loci were shown to contribute to the 
clustering of AIDs in children with multiple AIDs and in autoimmune families. Familial 
T1D, even with only second-degree relatives affected, leads to less severe onset of T1D 
in the index child. There was some evidence for a milder onset of T1D in children with 
additional AIDs. 
Conclusions 
This thesis provides current estimates of the frequency of additional autoimmunity in 
Finnish children with newly diagnosed T1D and in their relatives: at diagnosis 1.6% of 
children had additional AIDs, over 20% extended family members with T1D and over 
30% extended family members with other AIDs. These figures are in line with those 
reported previously internationally and in Finland. Differences in genetic etiology was 
implicated behind different phenotypes of clustering autoimmunity; familial T1D 
associated with DR4-DQ8 and T1D with CD autoimmunity with DR3-DQ2. Definitive 
associations of clustered autoimmunity with for example certain islet autoantibodies 
were not evident. Novel discoveries were the milder clinical onset of T1D in familial 
T1D even if only second-degree relatives were affected (readily explained by the 
increased awareness of the disease in these families), and the gender difference of girls 
having paternal and boys maternal second-degree relatives affected by T1D. This gender 
difference, transient anti-tTG among children with T1D at diagnosis, and the reported 
candidate non-HLA SNPs for clustered autoimmunity require validation by further 
studies. 
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Type 1 diabetes (T1D) is a chronic immune-mediated disease caused by destruction of 
the insulin producing β-cells of the pancreas. It is characterized by a prodrome period 
when autoantibodies to different β-cell antigens can be detected in the peripheral 
circulation as a sign of ongoing β-cell destruction although glucose homeostasis is still 
accurately maintained. When enough of the β-cells are destroyed and the insulin 
producing capacity is no longer sufficient, the patient becomes permanently dependent 
of exogenous insulin. 
In addition to vigilant glucose monitoring and insulin injections to maintain good 
metabolic control, patients with type 1 diabetes have a significantly increased mortality 
compared to the general population [1, 2]. Additionally, T1D puts a strain on the society 
and health care system with substantial cost. Thus, studies on the etiology, pathogenesis, 
natural course, and prevention of T1D are well justified.  
Increased understanding the etiology and pathogenesis of the immune reaction in 
T1D is crucial to efforts on trying to find effective prevention strategies for the disease. 
As this knowledge has accumulated, we have come to understand that in addition to 
mechanisms unique to the T1D autoimmune reaction, many of the proposed risk factors 
and pathways are shared with other autoimmune diseases (AIDs). Accordingly, patients 
with T1D and their relatives are at an increased risk not only for T1D but for other AIDs 
as well. For example, same HLA class II risk genotypes predispose for T1D and celiac 
disease (CD).  
This thesis aims at characterizing some of the factors associated with T1D 
pathogenesis and their relation to a more general propensity to autoimmunity.  
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Review of the literature 
Epidemiology of type 1 diabetes 
T1D was relatively uncommon until the 1950s when the incidence started to increase 
simultaneously in different parts of the world. Since then approximately 3% yearly linear 
increase in the incidence of T1D has been observed [3-5]. In 1999 it was estimated that 
the T1D incidence would increase by 40% from year 1998 to 2010 [4]. According to 
these estimates the incidence in Finland would have been 50/100 000 by 2010. The 
incidence reached 64/100 000 already in 2005 [6], however. The greatest increase in 
incidence has been among the youngest age group (0-5-year-olds) and in the countries 
with lower disease incidence previously [3, 5, 6]. Recently, an encouraging development 
has been described; reports of a plateau or even decrease in incidence have been seen 
around Scandinavia and Finland [7, 8]. 
Globally, T1D incidence is the highest in Finland and Sardinia. In general, the 
incidence is high in developed countries, and lower in countries with lower standard of 
living. The reasons for these differences are unknown, but supposedly related to differing 
environmental and genetic factors across the globe.  
Pathogenesis of type 1 diabetes 
T1D is an immune-mediated disease with destruction of insulin producing β-cells of the 
pancreatic islets. The strong association with the human leucocyte antigen (HLA) region, 
partial effects demonstrated by immunomodulatory treatments, co-occurrence with other 
autoimmune diseases, and the insulitis observed in patients with T1D are regarded as 
indications for autoimmune process causing T1D. However, the leucocyte infiltration in 
the pancreas is much less pronounced than for example in the non-obese diabetic (NOD) 
mouse or in affected tissues of other AIDs, e.g. rheumatoid arthritis or psoriasis [9, 10]. 
Similarly, the effect of immunomodulatory treatments is far from that seen in other 
AIDs. Accordingly, autoimmune origin of T1D – at least as a universal cause in all 
patients - has been challenged and the possibility of infections agents behind the disease 
has been raised. For the purpose of this thesis, however, T1D (with a range of other 
immune-mediated diseases) is grouped under AIDs. 
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T1D is caused by an interplay of genetic and environmental factors. Overwhelming 
majority of patients has a predisposing genotype in HLA and/or other risk regions. Only 
5-10% of the genetically susceptible will develop the disease in their lifetime, however. 
Accordingly, environmental risk factors are crucial in disease development. It is believed 
that multiple precisely timed environmental stimuli are needed to first initiate the 
immune-mediated destruction of β-cells, and second, to keep the process progressing 
instead of restorating [11, 12].  
Prediabetic disease process and humoral autoimmunity 
The asymptomatic prediabetic period during which β-cell destruction progresses varies 
in length from only few months to more than a decade [13]. The clinical disease with 
symptoms related to hyperglycemia will not develop until 80-90% of β-cells have been 
destroyed, and any remaining functioning β-cells are thought to be destroyed within a 
few years from the diagnosis. This view has been challenged recently, however, with the 
notions that majority of patients (73%) after five years from the diagnosis of T1D still 
secreted low levels of insulin in response to a meal [14]. 
The destruction of β-cells is regarded as a T-cell mediated process with the humoral 
immune reaction being mostly secondary to the ongoing cell destruction. Nevertheless, 
autoantibodies to β-cell antigens can be detected and are used as a marker of ongoing β-
cell destruction and in prediction of T1D. The major autoantibodies are islet cell 
antibodies (ICA), antibodies against glutamic acid carboxylase (GADA), insulin 
autoantibodies (IAA), autoantibodies against tyrosinphosphatase like protein/islet 
antigen 2 (IA-2A), and autoantibodies agaist zinc transporter 8 (ZnT8A). The schedule 
and order of appearance of different autoantibodies is highly variable [13]. One positive 
autoantibody is not necessarily a marker of significant risk for development of T1D, but 
the risk increases with increasing number of positive autoantibodies [15]. In a recent 
study, the risk to develop T1D by the age of 15-years was 0.4% for children without 
autoantibodies, 13% for children with one autoantibody, 62% for children with two 
autoantibodies, and 79% for children with three autoantibodies [16]. Risk factors 
associated with fast development of type 1 diabetes are the early appearance of 
autoantibodies (before the age of 3 years), the high-risk HLA genotype DR3-DQ2/DR4-
DQ8, and female sex [16].  
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Islet cell autoantibodies (ICA) 
ICA were the first T1D related autoantibody to be described [17, 18]. They are measured 
with an immunofluorescence method and thus measure immunoglobulin – mostly IgG – 
binding on multiple islet cell structures. Accordingly, ICA differ from other islet 
autoantibody modalities in that they are not specific to a single antigen but reflect 
reactivity to wider range of antigens. High levels of ICA reflect T1D related autoimmune 
destruction, but low levels of these autoantibodies are relatively common in relatives of 
T1D patients or general population and are thus assumed to represent non-progressive 
autoimmune reaction [19]. ICA are associated with younger age at onset, HLA-DR4-
DQ8, and female gender [20]. At diagnosis, 84% of Finnish children with T1D are 
positive for ICA [21].  
Insulin autoantibodies (IAA) 
IAA [22] are prevalent especially in young children and appear often as the first 
autoantibody to be detected [23]. They associate with the HLA-DR4-DQ8 haplotype 
[24] as well as INS and PTPN22 risk loci [25, 26]. As a first autoantibody to appear, IAA 
have a peak appearance before 2 years of age, and as a secondary autoantibody, IAA 
appear evenly over a wide age range [27]. In general, 44-92% of recent onset diabetic 
subjects [28], and 48-54% of Finnish children, have IAA at diagnosis of T1D [21, 29]. 
Glutamic acid decarboxylase autoantibodies (GADA) 
Autoantibodies against the 65 isoform of glutamic acid decarboxylase were first 
described as autoantibodies against the 64K protein [30], which was later identified as 
GAD65 [31]. These autoantibodies are associated with older age, female gender and 
presence of the HLA-DR3-DQ2 haplotype [20, 32]. If GADA are the first autoantibody 
to appear, they appearance is widespread peaking between 3-5 years of age and 
decreasing thereafter, whereas as a secondary autoantibody they usually appear early 
after IAA [27]. GADA are not restricted to T1D but are occasionally seen in other 
autoimmune conditions. Accordingly, GADA are suggested to be related to general 
propensity to autoimmunity [24, 33, 34]. GAD protein is expressed also in tissues outside 
pancreas, for example central nervous system, as seen in stiff man syndrome. GADA 
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persist longer after diagnosis than other autoantibodies [35]. At diagnosis, 65-68% of 
Finnish children with T1D have GADA [21, 29].  
Islet antigen 2 autoantibodies (IA-2A) 
Protein tyrosin phosphatase family protein IA-2 [36, 37] and IA-2ß [38] are major 
autoantigens in T1D. Both are enzymatically inactive membrane spanning proteins, that 
function in the regulation of insulin secretion [39, 40].  
These autoantibodies are associated with the HLA-DR4-DQ8 haplotype, and usually 
appear towards the end of the prediabetic process and are the most specific for the 
development of T1D [15]. IA-2A are rarely the first autoantibody to appear, but if they 
are, the process leads rapidly to clinical T1D [27]. Their predictive value for disease 
manifestation is very high, and they have been associated with rapid progression from 
islet autoimmunity to clinical disease [41]. An isolated IA-2A positivity has been 
proposed as a more aggressive phenomenon than isolated positivity to other 
autoantibodies [29]. At diagnosis, 75-79% of Finnish children with T1D have IA-2A 
[21, 29]. 
Zinc transporter 8 autoantibodies (ZnT8A) 
Autoantibodies against zinc transporter 8 molecule are among the most recently 
characterised T1D related autoantibody modalities [42]. They were discovered after the 
recognition of of this molecule as a pancreas specific transporter [43]. In fact, ZnT8 is 
specific for β-cells and participates in insulin secretion and transports zinc into secretory 
granules for insulin storage in hexamers bound by zinc [44]. Over 60% of patients with 
T1D have ZnT8A [28] whereas for patients with other AIDs the proportion is 10% [42]. 
Also, the gene encoding ZnT8, SLC30A8, has been associated with T1D [45]. ZnT8A 
positivity is associated with older age, lower probability of diabetic ketoacidosis at 
diagnosis, lower probability of having the HLA-DR3/DR4 genotype, and presence of 
neutral DR13-DQB1*0604 haplotype [46]. In Finnish children with T1D, 63% had 
ZnT8A at diagnosis [46]. 
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Etiology of type 1 diabetes 
Genetics of type 1 diabetes 
Traditionally, genes have been estimated to explain a major part of familial clustering of 
T1D. The concordance rate for monozygotic twins in Finland is 43% and for dizygotic 
twins 7% [47]. The HLA region is estimated to explain roughly 50% of the genetic 
predisposition to T1D [24] and to date over 50 other gene loci have been associated with 
T1D.  
Human leucocyte antigen (HLA) 
The most important genetic determinant of T1D risk with odds ratio (OR) 6-10 [48], is 
the HLA region in the short arm of chromosome 6 (6p21) [49]. This region encodes the 
major histocompatibility complex (MHC) I and II proteins that present antigens to T-
cells. The locus contains about 250 genes, and about 40-60% of these have immune 
related functions. A characteristic of this region is the complicated linkage 
disequilibrium block structure. [50]. The HLA region comprises three subregions: the 
telomeric class I, class III, and the centromeric class II region, with class II as the major 
T1D risk region. 
For T1D risk, the most important risk allele is HLA-DQB1 which is in linkage 
disequilibrium (LD) with HLA-DQA1 and HLA-DRB1 alleles and thus inherited as 
certain haplotypes. The DR4-DQ8 haplotype (DRB1*0401/2/4/5-DQA1*0301-
DQB1*0302) is the most common T1D predisposing haplotype in Finland, followed by 
DRB1*03-DQA1*05-DQB1*02 (DR3-DQ2) [51]. The HLA mediated T1D risk of an 
individual is determined by the two inherited haplotypes. The strongest risk genotype is 
the combination of the two risk haplotypes: DR3-DQ2/DR4-DQ8 and protection from 
T1D is dominant over risk alleles [52] (Table 1). By determining the HLA-DR-DQ 
haplotypes, the T1D risk of an individual can be estimated to be from 0,03% to 10%. 
Over 80% of all children developing T1D in Finland have a risk HLA genotype, whereas 
a protective genotype is present in 80% of healthy children [53]. Contribution of high-
risk HLA genotypes on T1D development has been reported to decreased in time since 
individuals with lower HLA dependent risk profile are developing T1D [54].  
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Other alleles in the HLA region are also relevant to T1D risk. Of the HLA class I 
alleles, HLA-B seems to play a larger role than HLA-A or C [56]. HLA-B39, especially 
B*3906, conveys high risk. Other associated alleles are B7, B35, B44, and B57 [57]. It 
has been proposed that HLA class II genes are involved in the initiation of the 
autoimmune process, but other gene regions in its progression [55, 58]. For example, 
HLA-B*39 has been reported to enhance and A*03 protect against the progression of 
beta cell destruction after seroconversion [57]. Gene-gene or gene-environment 
interactions have also been described for HLA class I and II genes with age at onset [59-
61]; the high risk DR3/DR4 has the highest frequency in the youngest patients, for 
instance. 
 
Table 1. Some of the common HLA class II haplotypes and genotypes conferring 
risk for T1D and some strong protective haplotypes and their odds rations in Finnish 
children. Modified from Ilonen et al. [55]. 
 
Haplotypes/Genotypes Odds ratio 










Some common risk genotypes  
(DR3) - DQA1*05 - DQB1*02 / 
DRB1*0401 - DQA1*03 - DQB1*0302 
14.7 
(DR3) - DQA1*05 - DQB1*02 / 
DRB1*0404 - DQA1*03 - DQB1*0302 
8.4 
DRB1*0401 - DQA1*03 - DQB1*0302 / 
DRB1*0401 - DQA1*03 - DQB1*0302 
7.6 
(DR8) - DQB1*04 / 
DRB1*0401 - DQA1*03 - DQB1*0302 
7.6 
(DR1/10) - DQB1*0501 / 
DRB1*0401 - DQA1*03 - DQB1*0302 
4.8 
(DR3) - DQA1*05 - DQB1*02 / 
(DR3) - DQA1*05 - DQB1*02 
4.1 
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Genetic risk loci outside the HLA region 
In addition to HLA, more than 50 other gene loci to date have been confirmed to modify 
T1D risk [62] [In March 2017, ImmunoBase (www.immunobase.org) lists 57 loci 
associated with T1D]. Among the largest effect sizes described are insulin gene (INS, 
11p15) and PTPN22 (1p13) which were discovered early by candidate gene techniques 
together with CTLA-4 (2q33) and IL2RA (Table 2). From 2006, genome wide association 
studies (GWAS) have multiplied the number of T1D risk genes. These studies started by 
GWAS of 4,253 cases and 5,842 controls [63], and soon evelvod to large studies 
combining different datasets; the largest to date included 9,934 cases and over 16,000 
controls [64]. Recently, results on ImmunoChip analyses on T1D have been published 
[65]. ImmunoChip is a microarray involving over 200,000 SNPs/insertion-deletions 
associated with 11 immune-mediated diseases.  
In general, if the HLA mediated risk for T1D is lower, the risk mediated by genes 
outside of the HLA region is relatively higher [66]. By genotyping these non-HLA genes 
in addition to HLA risk haplotypes, the development of future T1D or islet 
autoantibodies can be more reliably predicted [67-69]. 
In rare, monogenic diseases, the causal variant is usually a mutation in an exon of 
the causal gene leading to an altered amino acid composition and function. In complex, 
common diseases such as T1D, the associated genetic loci are usually common SNPs 
located outside gene bodies in regulatory regions. For many loci, the actual gene 
associating with the disease or how the mutation affects disease risk is unknown. Many 
are believed to exert their effects through gene expression (expression quantitative trait 
loci, eQTL) rather than affecting directly protein function. A SNP could for example 
influence the expression of a gene nearby rather than the gene it is situated in [70]. 
A limitation of GWAS is that the SNPs included are fairly common in the population 
(MAF>5%). This leaves out all the possible rare variants associated with T1D. Despite 
most being common SNPs, there are examples of rare loci associated with common 
disease. One example is IFIH1 in T1D risk; original discovery was a common SNP signal 
[71] which was later described being in LD with several rare variants [72].  
The effect sizes of non-HLA T1D risk loci are small, and in total they explain a much 
smaller proportion of the heritablity of T1D than does HLA. Together all the risk loci 
discovered so far are estimated to explain 80-85% of the disease heritability [73]. 
Although this proportion is considerably higher than for other complex diseases, a part 
of the heritability is still unexplained. It has been proposed that still unknown non-HLA 
genes with small effect sizes or structural variants (insertions, deletions, duplications, 
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copy number variants, translocations and inversions) remain to be discovered. 
Additionally, epistatic interactions between these genes, leading to effects beyond the 
multiplicative or additive effect, might explain the missing heritability, although studies 
on T1D have not found substantial evidence for this [74, 75]. Importantly, not all familial 
clustering is explained by genes, but most environmental risk factors are also shared by 
family members.  
The next paragraphs introduce some of the non-HLA risk loci. 
Insulin gene (INS)  
Insulin gene locus (11p15) has the strongest effect on T1D after HLA, and it was 
discovered already through linkage analysis [76]. Initially, the increased T1D risk was 
related to the variable number of tandem repeats (VNTR) region at 5’ end of the insulin 
gene, with long repeats associated with T1D. Later, two polymorphisms (rs689) INS-23 
A/T and +1140A/C have found in LD with the VNTR region [100], and might be in 
greater association with the causal variant than the VNTR region. The risk genotype 
increases T1D risk by lower insulin expression in thymus. This leads to low antigen 
presentation of insulin to the developing T cells and thus loss of central tolerance to 
insulin [101, 102].  
The risk genotype of INS has been associated with the presence of IAA [20, 26], 
more precisely with the appearance of IAA as the first autoantibody [27]. An association 
has been described with the development of islet autoimmunity, but not with the 
progression of autoantibody positivity to clinical T1D [103, 104]. These associations 
were not observed in those with GADA as the first detectable antibody, but only in 
patients with IAA as the first antibody [104]. Thus, it is proposed that INS is involved 
in the initiation of the autoimmune process against insulin rather than the progression 
and expansion of this process [103]. This locus is not associated with other immune-
mediated diseases.  
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new loci in 
the study: 
Candidate loci/genes Reference 
1970s  HLA class II  
1984  Insulin [76] 
1990s  HLA class I [77] 
1996  CTLA4 [78, 79] 
2004  PTPN22 [80] 
2005  IL2RA/CD25 [81] 
GWAS era:    
2006 1 IFIH1 [63] 
2007 3 12q13, 12q24 (C12orf30), 16p13 (CLEC16A) [82] 
2007 4 12q24, 12q13,16p13, 18p11 (PTPN2) [71] 
2007 0 CLEC16A [83] 
2008 1 12q13 (ERBB3) [84] 
2008 5 
4q27 (IL2), 6q15 (BACH2), 10p15 
(PRKCQ), 15q24 (CTSH), 22q13 
(C1QTNF6) 
[85] 
2008 6 RGS1, IL18RAP, TAGAP, SH2B3, 3p21 (CCR5), PTPN2 [86] 
2008 1 UBASH3A [87] 
2009 1 6q23 (TNFAIP3) [88] 
2009 1 12q13.3-q14.1 (KIF5A/CYP27B1) [89] 
2009 18 CD69/CLEC2D, GLIS3, IL10/PIK3C2B, etc. [66] 
2009 1 UBASH3A, BACH2 [90] 
2009 4 four rare IFIH1 variants [72] 
2009 2 (FHOD3) 18q12, Xp22 [91] 
2010 2 HERC2, IL26 [92] 
2011 3 13q22, 2p23, 6q27 [64] 
2011 1 FUT2 [93] 
2011 1 AGER [94] 
2011 1 IKZF1 [95] 
2011 1 SLC11A1 [96] 
2011 1 LOC729653 [97] 
2014 9 ITGB7, NRP1, BAD, CTSB, FYN, UBE2G1, MAP3K14, ITGB1, IL7R [98] 
2015 7 14q24.1, 17q21.31, 6q23.3, 1q32.1, 2q13, 4q32.3, 5p13.2 [65] 
2015 4 
1q24.3 (FASLG), 5q11.2 (ANKRD55), 











Protein tyrosine phosphatase, non-receptor type 22 (PTPN22)  
PTPN22 is a strong risk gene, discovered already before the GWAS era [80]. It is located 
on 1p13 and encodes LYP, a protein tyrosine phosphatase. This polymorphism causes 
an aminoacid change (arginine to tryptophan) at amino acid position 620, which leads to 
gain of function with increased inhibition of T-cell receptor signaling. The risk allele 
alters T cell and, to some extent, B cell function but exact mechanisms leading to 
increased risk for T1D is not known. There are several hypotheses, however: First, poor 
T-cell receptor signaling in thymus could lead to poor negative selection of autoreactive 
T cells. Second, there are high levels of LYP-expressing dendritic cells, whose function 
might be altered. Third, poor function of regulatory T cells allows the expansion of 
autoreactive T-cells [105]. PTPN22 has been associated with both the initiation of 
autoimmunity and progression from autoantibody positivity to clinical disease [103]. It 
predisposes also to multiple other AIDs [25]. 
Cytotoxic T lymphocyte antigen 4 (CTLA-4)  
This gene is located on 2q31 and encodes CTLA-4, which is a downregulator of T cell 
function. When discovered, the susceptibility to T1D and autoimmune thyroiditis (AIT) 
was mapped to a commont allelic variant at a non-coding region of CTLA4, which was 
correlated with lower messenger RNA levels of the soluble alternative splice form of 
CTLA4 [78, 79].  This SNP is strongly correlated with thyroid autoimmunity [78, 79] 
and thus found on patients with both autoimmune thyroid disease and T1D [106]. 
Fucosyltransferase 2 (FUT2) 
The FUT2 gene (19q13.4) codes for α(1,2)-fucosyltransferase, which synthesizes the H-
antigen. This antigen is the precursor of the ABO blood group antigens on intestinal 
mucosa and body fluids. Being homozygous for the variant of nonfunctional protein 
(W143X rs601338A>G in Europeans), leads to nonsecretory status whereby no ABO-
antigens are expressed in the intestine or saliva. The nonsecretors are resistant to 
norovirus infection, have a slower progression of HIV infection and protection from 
Helicobacter pylori infection. For these reasons, positive selection for the defected A 
allele has been suggested, as this is the major allele over the wild type G in many 
populations. On the other hand, the nonsecretors are more susceptible to Streptococcus 
infection, Candida albicans infection, Crohn’s disease and T1D. FUT2 is a recessive 
T1D risk gene [93]. 
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Interferon induced helicase C domain 1 (IFIH1) 
 IFIH1 codes for an intracellular pattern-recognition receptor which recognized double 
stranded viral RNA. It is involved in recognizion of picornaviruses. As enteroviruses 
belong to this family, the association might represent the link between virus infections 
and T1D pathology. The common nonsynonymous Ala946Thr variation on the gene 
(2q24) leads to T1D susceptibility [63] and later rare independent variants of the same 
gene have been discovered [72]. These variants, which lead to altered protein function, 
are associated with protection from T1D, leading to the suggestion that normal IFIH1 
function increases T1D risk.  
Epigenetics in type 1 diabetes 
Epigenetics can be defined as processes that affect inheritance but do not depend on 
changes in DNA sequence. Examples of such processes are DNA methylation, gene 
silencing, inactivation of one of the X chromosomes in females, regulatory actions of 
noncoding RNAs (microRNAs, long noncoding RNAs), and making the DNA strand 
inaccessible for transcription factors by modifications on chromatin restructuring around 
histone structures [107]. In AIDs, epigenetic changes in either the effector immune cells 
or their target organs could affect the development of the disease. There are data 
indicating that epigenetic factors play a role for example in T helper cell differentiation, 
central tolerance induction, and autoantibody production by B cells. Especially the 
female preponderance seen in most AIDs could be mediated by epigenetics, perhaps by 
demethylation of the inactivated X chromosome in females [107]. In T1D, the histone 
methylation profile of T cells has been described aberrant for example in the promoter 
region of CTLA4 [108], and T1D associated DNA methylation variable positions have 
been discovered from T1D discordant twins [109]. 
Environmental risk factors 
Genetics alone can not explain the increase in T1D incidence over recent decades or the 
disconcordance between monozygotic twins. Accordingly, despite 70% of the general 
population carrying predisposing HLA genotypes, only 3-7% of those with a 
predisposing HLA genotype develop T1D. The incidence of T1D in children migrating 
to another region is at the level of the current region, not the region of origin [110]. 
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Further, the incidence of T1D in Finland is six times higher compared to Russian Karelia 
despite similar genetic background [111]. These findings suggest the role of 
environmental factors in the etiology of T1D.  
Environmental factors have been suggested to play a role in different stages of the 
disease process; some are believed to act as triggers in the initiation of the immune-
mediated β-cell destruction, and some as promoters carrying this process forward. For 
example, in a German study, cesarean section associated with progression of islet 
autoimmunity to T1D, but not with the appearance of autoantibodies [112].  
Despite a large range of hypotheses, T1D related environmental factors remain 
poorly defined. Most of the suggested environmental factors can be grouped under diet, 
infections, intestinal microbiota, toxins, or factors causing β-cell stress. 
Diet 
Different aspects of diet have been associated with T1D risk. Most of these relate to early 
infant feeding (e.g. breastfeeding, introduction of cow’s milk or solid foods), but dietary 
factors later in life are also suggested (e.g. vitamin D or long-chain polyunsaturated fatty 
acid intake) 
Breastfeeding as a protective factor for T1D development is still an open issue, 
although a meta-analysis showed limited protective effect [113]. Also breastfeeding 
during introduction of cereals in the infant’s diet has been shown to protect from T1D 
[114]. Early exposure to cow’s milk proteins has been proposed as a predisposing factor 
for T1D, but the recent studies have been contradictory. In Trial to Reduce IDDM in the 
Genetically at Risk (TRIGR), children with genetic risk for T1D received extensively 
hydrolysed infant formula, whenever breast milk was not available, as opposed to regular 
infant formula. In a smaller pilot study, weaning to extensively hydrolysed formula 
showed protective effect on development of islet autoimmunity [115], but the larger 
multinational TRIGR study did not confirm these findings by the first seven years of life 
[116]. Also increased intake of cow’s milk later in life has been reported as a risk factor, 
but these findings have been contradicted as well [117, 118]. 
Both early (<4 months of life) and late (>6 months) introduction of solid foods, and 
especially gluten, in the infant’s diet has been proposed a risk factor for islet 
autoimmunity [119, 120]. In a Finnish study, early exposure (<4 months) to root 
vegetables increased risk for islet autoimmunity [121].  
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Vitamin D deficiency has been proposed as a risk factor for T1D. The seasonal 
endogenous production of vitamin D by sun light could explain the lower rates of 
diagnosis of T1D in the summer. Also, lower or absent vitamin D supplementation has 
been implicated to increase the disease risk and higher serum 25-hydroxyvitamin D 
levels in pregnancy have been associated with decreased risk of T1D in the offspring. 
All these findings have been contradicted as well, and the question remains unanswered 
[11]. 
Administration of probiotics before the age of 28 days has been associated with 
decreased risk of islet autoimmunity. This finding was limited to children the high-risk 
HLA genotype DR3-DQ2/DR4-DQ8 and was absent among children with other 
genotypes [122]. Other nutritional factors associated with T1D risk are lower intake of 
long-chain polyunsaturated fatty acids and increased intake of nitrites, nitrates, or 
nitrosamines through food or water [11]. Also, advanced glycation end products and 
their receptor have been implicated in T1D development [123, 124].  
Viral infections 
Viruses have been implicated in T1D disease development, first due to the seasonal 
patterns of the two diseases coinciding in autumn and winter and later with serological 
and molecular methods for virus detection in patients. The most convincing evidence 
exists for enteroviruses (especially group B coxsackie viruses), although some reports 
for the involvement of other viruses, e.g. rotavirus, cytomegalovirus, and parvovirus, 
exists. Persistent infections of enteroviruses in the human pancreas and gut have been 
described in T1D. Enteroviruses along with some other viruses can cause diabetes in the 
NOD mouse model and these viruses infect and lyse cultured human islets in vitro [125].  
The current hypothesis is that enteroviruses cause acute infection in the pancreatic 
islets leading to development of islet autoimmunity. In those individuals who fail to 
eradicate the virus, the infection continues in a slowly replicating chronic manner leading 
eventually to overt diabetes [126]. The hypothesis is supported by the notion that an 
excess in enterovirus infections is detected early in life already before seroconversion. 
Controversially, as T1D incidence has increased, incidence of enterovirus infections has 
decreased. To explain this phenomenon, so called polio hypothesis has been proposed; 
as the enterovirus exposure decreases, the immunity of newborns through maternal 
antibodies gets weaker and thus they are more susceptible to diabetogenic effects of 
enteroviruses. Vaccination agaist enteroviruses is an attractive candidate for primary 
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prevention of T1D and such intervention studies are also needed to determine the 
causality of enteroviruses in T1D [126]. 
Hygiene hypothesis 
The hygiene hypothesis was first described for allergic diseases [127] and has later been 
extended to AIDs. The original hypothesis proposes that the reduced frequency of 
microbial infections in early life leads to increased risk to develop allergic or immune-
mediated diseases. Evidence supporting the role of infections exists especially for atopic 
diseases, as e.g. measles, Helicobacter pylori, and Toxoplasma gondii infections are 
inversely associated with allergic diseases [128].  Not all studies support the hypothesis 
in its original form, however, as for example respiratory infections in early life 
(<6months of age) have been associated with increased risk of islet autoimmunity [11]. 
Accordingly, the hypothesis for association of microbial exposure and development of 
T1D now focuses more on commensal microbiota in the living environment rather than 
exposure to human pathogens i.e. the biodiversity hypothesis. To this end, the decreased 
biodiversity related to modern city living has been shown to alter human microbiota 
which affects the occurrence of allergic and inflammatory diseases [129]. A concrete 
example is that having an indoor dog in the family during the first year of life associates 
with protection from development of T1D related autoimmunity [130].  
Microbiota 
During recent years, microbiota has emerged as a new area of research due to 
development of analysis methods. The gut has a microbial flora with 100-fold more 
genes than the human genome, and we do not yet fully understand its functions. The 
colonization of the gut happens at birth – although some evidence exists for non-sterile 
environment in utero - and is mainly attributed to the microbial flora of the mother and 
family members. The microbiome develops through the first years of life and adult type 
microbial diversity is usually reached after the first three years of life. Mode of delivery 
(vaginal or cesarean) as well nutrition significantly affect the microbial flora. Several 
studies now indicate that lower gut microbial diversity is present in children with T1D 
related autoantibodies. Also, an abundance of butyrate- and lactate-producing bacteria 
has been described in children with islet autoantibodies. Considering these findings, it 
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seems that intestinal microbiota plays a role in progression of islet autoimmunity to 
clinical disease rather than initiation of autoimmunity [131]. It is still unclear whether 
this intestinal dysbiosis causes T1D development or whether it is a consequence of some 
other T1D related risk factor [132]. Recently, results of the DIABIMMUNE study have 
revealed marked differences in development of early intestinal microbiome in Finnish 
and Estonian infants compared to Russian Karelian infants. For example, Bacteroides 
species are dominant in Finland and Estonia, and the lipopolysaccharides (LPS) 
produced by these species (namely B. dorei) differ from those most abundant in Russians 
(namely Escherichia coli LPS). B. dorei LPS inhibits endotoxin tolerance and signaling 
of the innate immune system and and does not decrease incidence of autoimmune 
diabetes in NOD mice [133]. 
Factors inducing β-cell stress 
Accelerator hypothesis proposes that insulin resistance related to higher weight gain or 
body mass index (BMI) results in the initiation of T1D related autoimmunity. The 
hypothesis has later evolved to implicate that a multitude of factors leading to increased 
insulin demand might have a role in development of T1D. Such factors are for example 
rapid growth, puberty, trauma, infections, overweight, and psychological stress [11].  
Familial type 1 diabetes 
Approximately 10-12% of children diagnosed with T1D have a first-degree relative with 
T1D at diagnosis, and if follow-up is continued for decades, this number increases to 
over 20% (Table 3). Compared to general population, first-degree relatives of T1D 
patients are at an 8-15-fold increased risk for T1D [134-140].  
The proportion of children with T1D who have second-degree relatives with T1D has 
been reported to be 5-16% (Table 3). Compared to general population, the risk of T1D 
for second-degree relatives is approximately two-fold [134, 141]. Cumulative incidence 
of T1D for siblings of T1D patients is 3-6% by age of 20 years and the life time risk for 
parents is 2-6% (Table 4). 
The proportions of familial T1D have not changed over time and the increase in 
incidence among first-degree relatives has been the same as for the whole general 
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population [137, 142]. A correlation exists, however, for the incidence of T1D in a 
population and the prevalence of familial disease [143]. Age at onset of T1D is higher 
in families with multiple children with T1D compared to families with only one affected 
child [144].  
A peculiar sex-dependent inheritance pattern has been reported for T1D; fathers 
transmit the disease to their offspring more often than mothers [137, 160]. Appropriately, 
4-7% of children have a father with T1D at diagnosis compared to 1.5-3% an affected 
mother (Table 3). Risk of T1D by the age of 20 years in offspring of fathers T1D was 
7.8% and in offspring of mothers 5.3%, giving a 1.7-fold risk. This risk increases if the 
father was diagnosed with T1D in early childhood [137]. Additionally, there are reports 
on fathers transmitting T1D preferentially to daughters and mothers to sons [137, 138, 
143], although not all studies have found this pattern [142, 160].  
Reasons for the preferential transmission from diabetic fathers are still under debate. 
Many of the proposed mechanisms are genetic; greater haplotypic preservation of 
susceptibility gene loci in male patients (i.e. lower recombination frequency during 
gametogenesis), genetic susceptibility being preferentially transmitted from fathers 
regardless if they are diabetic or not, or genetic imprinting i.e. differential expression of 
the disease depending on the sex of the parent transmitting the susceptibility alleles [160, 
161]. Evidence for these genetic differences is limited, however. For example, 
preferential transmission of T1D susceptibility from either parent has not been evident 
for HLA [162] or other loci; only one of 17 T1D loci showed some biased maternal 
transmission [163]. As risk of T1D development is similar in patients with fathers or 
siblings with T1D, and lower in patients with affected mothers, a protective effect of 
T1D in mothers has been suggested. Accordingly, a hypothesis of a protective influence 
on insulin secretion capacity of the fetus in diabetic pregnancies has been suggested. 
This hypothesis is supported by the epidemiological finding of a higher risk of T1D in 
children born before maternal diagnosis of T1D compared to children born after the 
diagnosis of the mother [164]. Additionally, maternal insulin treatment has been 
suggested to induce expansion of T regulatory cells (Tregs, CD4+CD25highFOXP3+ T 
cells) in the fetus: In a Finnish cohort of newborns, the proportion of circulating Tregs 
was higher in children with maternal T1D compared to children with unaffected mothers. 
In addition, insulin stimulation induced upregulation of molecules involved in activation 
of Tregs only in offspring of mothers with T1D [165].  
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An additional explanation for the lower risk for T1D in children with mothers with T1D 
would be selective spontaneus abortion of pregnancies with fetuses having high genetic 
risk for T1D. In fact, risk for miscarriage is higher in women with diabetes compared to 
healthy women and this risk increases if diabetes was diagnosed at an early age. This has 
been explained by hyperglycemic state during fertilization and early pregnancy [137]. 
Fertility is reduced in women with T1D, but also in men with T1D, albeit to a smaller 
degree [166, 167]. Older maternal age at birth has been reported as a protective factor for 
T1D, a finding independent of birth order, maternal age at first pregnancy, interval 
between pregnancies or diabetes diagnosis before or after pregnancy [164].  
Familial clustering of T1D is likely caused by both genetic and environmental risk 
factors. The risk-associated HLA genotypes have been observed more often in familial 
T1D [145, 168-170] although not all studies have found significant differences [171, 
172]. It has been proposed that familial T1D is mainly attributed to HLA class II genes 
and not genes outside the HLA region [74]. Support comes from GWA studies where the 
effect sizes for non-HLA loci were smaller in families with affected siblings than in 
sporadic cases [66].  
Two studies have noticed no differences in diabetes-associated autoantibodies, e.g. 
insulin antibodies (IAA), glutamic acid decarboxylase antibodies (GADA) [145], or islet 
cell antibodies (ICA) [145, 168] suggesting similar pathogenetic mechanisms in familial 
and sporadic forms of the disease. A study from Israel reported, however, higher 
frequencies of IAA as well as a higher number of positive antibody responses among 
familial cases [173]. The development from autoantibody positivity to clinical T1D 
seemed similar in a large prospective report for cohorts of familial T1D and sporadic 
cases recruited from the general population [16]. 
Clinical status of the child at diagnosis is less severe in families with prior experience of 
the disease in a first-degree family member [145, 173, 174]. This can be easily explained 
by the better awareness and alertness of the family and the family physician of the early 
symptoms of T1D. Consequently, T1D is diagnosed earlier leading to milder onset and 
for example lower prevalence of diabetic ketoacidosis. During follow-up after T1D 
diagnosis, children with familial diabetes had higher long-term HbA1c in Denmark [175].  
Familial T1D has been associated with younger age at onset of T1D although not by 
all studies. An Italian study reported earlier age at onset in children with family history 
of T1D in second-degree relatives compared to sporadic cases (5 vs. 8 years, P=0.001) 
[156]. 
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Associations with general autoimmunity 
Patients with T1D are at an increased risk for other AIDs, for example CD and 
autoimmune thyroid disease [176]. Relatives are at an increased risk for T1D and other 
AIDs as well. This clustering of diseases could be attributed to genetic and environmental 
factors predisposing not just to one AID but to autoimmunity in general.  
Epidemiology of additional autoimmunity 
T1D is associated with other autoimmune/immune-mediated disorders such as 
autoimmune thyroiditis (AIT), celiac disease (CD), Addison’s disease, pernicious 
anemia, rheumatoid arthritis, and multiple sclerosis (MS). AIT is the most common 
comorbid condition with a prevalence of 15-30%. CD has been reported in 4-9%, 
Addison’s disease in 0.5%, autoimmune gastritis in 5-10%, and vitiligo in 2-10% of 
patients with T1D [177].  Increased risk of multiple autoimmune manifestations exists 
already at diagnosis of T1D but increases significantly with follow-up [178, 179]. After 
screening for autoantibodies at diagnosis, 6% of children with T1D have been reported 
to have another AID [180]. Celiac disease (1.5-3.3%) [180-183] and AIT (0.6-3.1%) [33, 
180, 183] are the most common conditions already present at T1D diagnosis. For 
example, older age and female gender are risk factors for developing additional 
autoimmunity in T1D patients (Table 5).  
The risk for AIDs is increased also in the relatives of T1D patients. In a recent meta-
analysis, first-degree relatives of T1D patients were at significantly increased risk for 
Addison’s disease, AIT, ancylosing spondylitis, CD, MS, pernicious anemia, primary 
biliary cirrhosis, psoriasis, RA, SLE, vitiligo, and Wegener’s granulomatosis [188]. AIT, 
CD and rheumatoid arthritis are the most common conditions [151, 178, 189, 190]. The 
risk for the relatives is even greater in families where the index child with T1D has 
multiple AIDs [189], and the risk for an additional AID is higher if the patient is already 











Table 5. Some reported risk factors for development of additional autoimmune 
diseases in T1D. 
 
Risk factors for developing additional autoimmune 
diseases (AID) in addition to type 1 diabetes (T1D) References 
Female gender [34, 178, 179, 184] 
Long duration of T1D [34] 
Older age at onset of T1D [34] 
Older age [34, 184] 
Positive family history of AID [34] 
Positivity and high titers of GADA  [34] 
Negativity or low levels of IA-2A [34] 
Risk factors for developing celiac disease (CD):   
Female gender [34, 185] 
Long duration of T1D [34] 
Young age at onset of T1D [34, 182, 185] 
First-degree relative with an AID [34, 185] 
IA-2A negativity [34] 
HLA-DR3-DQ2 [34, 186, 187] 
 
 
Due to the co-occurrence of AIDs, screening of patients with T1D has been 
recommended. In Finland, anti-tTG and thyroid function tests are performed at 
diagnosis and at regular intervals (every one or two years) in children diagnosed 
with T1D. Other markers of AIDs are measured if symptoms occur or suspicion 
is otherwise raised. These protocols may differ locally, however. Different 
recommendations have been suggested by international organizations (Table 6). 
Additionally, regular measurements of ACA and PCA have been suggested by 
some [191, 192].  
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Clinical autoimmune thyroiditis (AIT, Hashimoto’s thyroiditis and Graves’ disease) is 
the most common AID associated with T1D. Hashimoto’s thyroiditis (manifesting mostly 
as hypothyroidism) is more common than Graves’ disease (hyperthyroidism). Thyroid 
autoimmunity is manifested as autoantibodies against thyroglobulin (Tg-Ab), 
thyreoperoxidase (TPO-Ab) and TSH receptor. These antibodies are present in 12-23% 
of pediatric patients with T1D and in 20-40% of adult patients with T1D [192]. The 
prevalence is higher among girls, and increases with increasing age and duration of T1D. 
Of those T1D patients with positive thyroid autoantibodies, 6-72% also have clinical or 
subclinical thyroid dysfunction, whereas of the healthy controls with these 
autoantibodies, only 0-25% [191]. Clinical hypothyroidism is diagnosed in 4-18% of 
T1D patients [192]. 
Thyroid autoimmunity usually develops a few years after the T1D diagnosis and only 
very rarely precedes it. Diabetic ketoacidosis and disturbances in glycemic control affect 
thyroid function and can cause a great number of false positive findings if thyroid 
function is assessed at diagnosis: 19% of pediatric patients had thyroid hormone 
disturbances at diagnosis and only 2.7% required treatment after two years of follow-up 
[196].  
Celiac disease (CD) 
The second most common co-occurring AID in T1D is CD; biopsy-proven CD in 
pediatric patients with T1D is diagnosed in 4-6% [197-199]. In CD, intestinal mucosa is 
destroyed by the immune system in response to gluten containing cereals (wheat, rye, 
barley). Treatment is life-long gluten-free diet. Celiac autoimmunity is usually evident 
by detectable autoantibodies: tissue transglutaminase autoantibodies (anti-tTG), 
endomysial antibodies (EMA), and autoantibodies against deamidated gliadin peptides 
(DGP) [200]. CD is discussed in detail later in this section. 
Adrenal autoimmunity 
Autoimmune reaction targeted against adrenal tissue results in adrenal insufficiency 
(Addison’s disease, AD) with impaired production of glucorticoids, mineralocorticoids 
and androgens. Adrenocortical autoantibodies (ACA) are detected in 0-4% of patients 
with T1D compared to 0-0.7% of controls [191]. These autoantibodies recognize the 
adrenal 21-hydroxylase, a P450-cytochromal enzyme. In Finnish pediatric population, 
2.3% of T1D patients developed ACA during the follow-up of 3-4 years, but none 
developed clinical adrenal dysfunction [201]. Usually, clinical disease develops in 3.3-
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40% of T1D patients with ACA [191]. The prevalence of co-occurring AD and T1D 
(Schmidt syndrome) in adult patients is 0.8-1.9% [192].  
Autoimmune gastritis 
Autoimmune gastritis is an autoimmune reaction against the gastric H+/K+ ATPase 
enzyme in gastric parietal cells. The disease starts as a symptomless gastritis and leads to 
atrophic gastritis and eventually pernicious anemia (vitamin B12 and iron deficiency). 
The process is manifested as autoantibodies against gastric parietal cells (parietal cell 
antibodies, PCA). The prevalence of PCA among T1D patients is 3-34% (5-8% in 
pediatric patients), and among the general population 0-13% [191, 192]. Atrophic 
gastritis develops in 43-50% of T1D patients positive for PCA, but pernicious anemia 
develops only in 1-23% [191]. Overt gastritis in pediatric T1D patiens is rare. 
Other autoimmune diseases 
Vitiligo is manifested as white spots on the skin due to loss of epidermal 
melanocytes. It is estimated to be 10-20 times more frequent in T1D patients than 
in general population with prevalence in pediatric T1D patients reported to be 6% 
[192].  
T1D and MS cluster together despite their conflicting HLA predisposition; HLA-
DRB1*1501-DQA1*0102-B1*0602 predisposes to MS but protects from T1D [202]. In 
a Danish cohort, patients with T1D were at a three-fold increased risk for MS [135]. 
Juvenile idiopathic arthritis is associated with T1D; in a multicenter study the 
prevalence was 0.2% in pediatric T1D patients compared to 0.05% in general population 
[203].  
Autoimmune polyglandular syndromes (APS) are characterized by the presense of 
multiple AIDs in an individual. APS-1, also known as autoimmune polyendocrinopathy-
candidiasis-ectodermal dystrophy (APECED), is a monogenic, autosomal recessive 
condition caused by a mutation in autoimmune regulator gene (AIRE). These patients 
develop adrenal insufficiency, hypoparathyroidism, and mucocutaneous candidiasis 
usually already during childhood. Other associated conditions are T1D, vitiligo, alopecia, 
hepatitis, pernicious anemia, primary hypothyroidism, hypergonadotropic 
hypogonadism, and malabsorption. APS-2 is more common in adults and manifests as 
adrenal insufficiency and other AIDs including T1D. APS-3 involves multiple endocrine 
gland AIDs but usually not adrenal insufficiency. APS-2 and APS-3 are polygenic 
conditions associated with HLA class II haplotypes [192, 193]. 
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Traditionally, autoimmune and atopic diseases are thought to arise from different 
pathways of immune reactions and thus rarely coexists. Atopic diseases are driven by 
Th2-type immune response whereas Th1-type in dominated in AIDs. As these two are 
mutually inhibitory, in theory the two types of diseases should not coexists. There are 
data to support this view: a meta-analysis found a reduction in prevalence in asthma in 
T1D patiens, although for other atopic diseases the results were inconclusive [204]. In 
Danish twins, the risk for atopic dermatitis was clearly decreased in patiens with T1D 
[205]. There are, however, recent data that place these two disease modalities closer 
together [50, 206]. Asthma prevalence among children and adolescents with T1D in the 
USA was 10.0% whereas the estimate for general population was 8.7% [207]. The 
incidences of T1D and asthma/atopic eczema correlate at country-level, both increasing 
in developed countries [208]. This points to mutual predisposing environmental risk 
factors, with reduced microbial exposure as the most prominent [209]. When studying 
the Th1/Th2 cytokine profiles of patients with both T1D and asthma, it has in fact been 
discovered that these patients have a unique secretory pattern, which combines elements 
from both diseases [210-212]. These diseases also share predisposing genetic factors 
[213].  
Etiology and pathogenesis of additional autoimmunity 
Risk factors for many AIDs are shared. For example, almost all AIDs are more prevalent 
in women/girls. T1D is a striking exception to this rule; in children under the age of 15, 
there is a male excess in countries with high T1D incidence whereas many low incidence 
countries report female excess. After puberty, however, populations of European origin 
report a clear male excess in T1D [214]. Norwegian data suggests that similar male excess 
in T1D has been evident since the beginning of the 20th century [214]. In MS, however, 
the risk for the disease is higher in female patients, but this situation has developed 
relatively recently as the sex ratio used to be equal some 50 years ago [215]. 
Similar environmental risk factors have been associated with many AIDs. For example, 
enterovirus infections have been suggested in T1D and Epstein-Barr virus (EBV) in RA, 
MS, and Sjögren’s syndrome [216]. The gastrointestinal tract has been implicated as a 
site of initiation of autoimmunity in multiple AIDs. Accordingly, nutritional factors such 
as duration of breast feeding, vitamin D deficiency, or timing of introduction of solid 
foods such as cow’s milk or gluten containing cereals have been studied in many AIDs. 
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This has led to similar attempts at primary prevention of different immune mediated 
diseases. For example, extensively hydrolyzed formula has been studied in allergic 
diseases in addition to T1D. In a German study, children with parental history of atopy 
received hydrolysed formula as breast milk substitute if necessary for the first four 
months of life. A reduction of risk of allergic dermatitis was evident and the effect has 
now lasted up to the age of 15 [217]. A recent meta-analysis on hydrolysed formula and 
risk of allergic diseases does not support these claims, however [218]. Moreover, a meta-
analysis from the same group concluded that no evidence exists for timing of allergenic 
food introduction and development of CD, T1D or other AIDs. Reduction of egg allergy 
and peanut allergy, however, were reported for egg introduction at 4 to 6 months and 
peanut introduction at 4 to 11 months [219]. 
Hygiene hypothesis, i.e. the decreased microbial exposure during childhood 
increasing the incidence of atopic diseases, has been extended from allergic diseases to 
development of autoimmunity. Accordingly, sharp contrast exists between prevalences 
of immune-mediated diseases in Finland and Russian Karelia; the incidencies of T1D and 
CD, as well as prevalences of thyroid autoantibodies and allergen specific IgE were 3-6 
times higher in Finland [128]. These two geographical areas are neighbourgs with limited 
differences in HLA genetics but marked differences in living conditions and 
socioeconomic status. For example, many infections such as Helicobacter pylori, 
hepatitis A, and Toxoplasma gondii are still common in Russian Karelia but infrequent 
in Finland. Also, the microbial composition of household dust differs in these areas in 
accordance with the hypothesis of decreased biodiversity increasing the risk of immune-
mediated diseases [128]. Accordingly, contact with farm animals, indoor dogs or cats, 
having multiple siblings, or attending day care early have been implicated in protection 
from many allergic and autoimmune diseases [128]. 
These results highlight that, despite the multiple phenotypes of autoimmunity, many 
proposed etiological factors are strikingly similar. This is understandable as the reactivity 
of the immune system and loss of tolerance to self-antigens are proposed mechanism 
behind all. The phenotypes of these AIDs are very different, however. Factors 
determining the target tissues for these specific autoimmune phenotypes are unknown. 
Some unique genes have been described, e.g. INS is a risk locus only for T1D and TSHR 
(encoding TSH receptor) only for AIT. 
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Genetics of autoimmunity 
HLA region 
HLA region is associated with all AIDs. The haplotypes DR4-DQ8 and DR3-DQ2 are 
the major contributors to genetic risk of T1D among Caucasians. Both of these, but 
especially DR3-DQ2, have been associated also with other AIDs. CD and T1D share the 
same HLA background, as 90% of patients with CD have DR3-DQ2 [220] and an 
overwhelming majority of the rest DR4-DQ8 haplotype. DR3-DQ2 has been associated 
also with other conditions, such as SLE, myasthenia gravis, idiopathic inflammatory 
myositis, stiff person syndrome, and Addison’s disease [221]. Addison’s disease has been 
associated with the rare DR3-DQ2/DRB1*0404-DQ8 genotype; 30% of patients carry 
this genotype compared to less than 1% of the general population [222]. Different 
DRB1*04 alleles are associated with rheumatoid arthritis, autoimmune hepatitis, 
alopecia, juvenile idiopathic arthritis, and Crohn’s disease [221]. 
Genes outside the HLA region 
Most genes associated with AIDs are shared with other AIDs [50, 223]. In a recent 
review, 127 non-HLA loci were associated with the six common AIDs (T1D, rheumatoid 
arthritis, CD, AIT, psoriasis, and SLE). More than half of these SNPs were shared with 
other AIDs, for example CD and RA as well as CD and T1D share over 50% of the 
associated loci [223]. To make matters more complicated, the risk allele is not always the 
same between diseases. For example, for the PTPN22 SNP rs2476601, the A allele yields 
susceptibility to T1D and RA [66] and G allele for Crohn’s disease [92]. IL10, IL27, and 
IL18RAP also have opposite direction of effect for T1D or IBD [92], and IL18RAP 
opposite effect for CD [86]. Accordingly, it has been suggested that, genetically, T1D is 
closest to other AIDs with autoantibodies, particularly juvenile idiopathic arthritis, 
whereas T1D is least similar to ulcerative colitis [65].  
The genes associated with AIDs can be grouped under three major pathways; genes 
involved in T cell differentiation; immune cell activation and signaling; and innate 
immunity and TNF signaling. Of the genes not included in these pathways, the genes 
associated with inflammatory bowel diseases (Crohn’s disease and ulcerative colitis) 
form a distict group, as do genes associated with other cytokines and chemokines [50]. 
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Most AIDs have susceptibility genes involved in all main three pathways highlighting 
the common overlap of pathogenesis. Despite extensive studies, only 50% of the assumed 
heritability of autoimmunity has been explained [223]. 
Celiac disease 
Celiac disease (CD) is an immune-mediated disease evoked by dietary gluten and related 
prolamins and characterized by autoantibodies, predisposing HLA genotypes, and 
enteropathy. The HLA predisposition (DQ2 and DQ8) is shared with T1D, and 
accordingly patients with one disease and their relatives are at an increased risk for the 
other [189, 224]. Other risk groups for development of CD are for example patients with 
Down syndrome, AIT, Turner syndrome, IgA defieciency, and first-degree relatives of 
CD patients [200]. CD is treated with a life-long gluten free diet, which allows the 
intestinal mucosa to heal, alleviates symptoms and results in disappearance of 
autoantibodies. 
The clinical symptoms and signs of CD are variable and may include systemic 
manifestations in addition to enteropathy. Classic CD symptoms and signs in children 
include diarrhea, weight loss, failure to thrive, and abdominal pain. Additionally, CD can 
cause iron deficiency anemia, aphthous stomatitis, and dermatitis herpetiformis rash. 
However, increasing proportion of patients are asymptomatic at the time of diagnosis 
[200].  
Tissue transglutaminase type 2 (tTG) is the primary autoantigen in CD [225], and 
accordingly tissue transglutaminase autoantibodies (anti-tTG) are used for the screening 
of CD autoimmunity. Endomysial antibodies (EMA) are detected by immunofluorescent 
methods and are the most specific method for detection of CD autoimmunity. Also 
antibodies against deamidated gliadin peptides (GDP) are often detectable especially 
among very young children with CD. Autoantibodies against native gliadin (anti-gliadin 
antibodies, AGA) are not sensitive or specific enough for the detection of CD [200].  
CD related enteropathy is characterized by a wide range of changes from increased 
infiltration of the mucosa by the cells of the immune system to partial or total villous 
atrophy. Marsh classification is used to grade the severity of the observed enteropathy (0 
– no villous atrophy, 3 – villous atrophy). Accordingly, histological evaluation of 
intestinal biopsy samples is the golden standard for CD diagnosis. However, The 
European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) 
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guidelines from 2012 recommend that intestinal biopsy may be omitted in symptomatic 
children with predisposing HLA haplotypes and high IgA-anti-tTG levels (>10 times of 
the upper limit of normal) and EMA [200].  
Epidemiology of celiac disease in T1D 
T1D patients are at 5-7-fold increased risk of CD [198]. Compared to approximately 1% 
in the general population [226, 227], the prevalence of biopsy-proven CD in pediatric 
patients with T1D is 4-6% [197-199]. The variation is large, however, ranging from 
Finland’s 2.4% to Algeria’s 16.4% (Table 7). CD is mostly diagnosed after the T1D 
diagnosis. Accordingly, only 0.5% report CD before T1D diagnosis [181, 182, 197, 228, 
229]. At T1D diagnosis, 3.9% to 16.8% of patients are positive for anti-tTG (Table 7).  
 
Most patients with CD are asymptomatic at diagnosis, i.e. are found by screening. In 
the US, only 40% of new pediatric CD cases and 59% of adult cases were symptomatic 
[250]. Most of them do feel better after initiation of gluten free diet, however. Among 
T1D patients, 74% of those diagnosed with CD were asymptomatic [238]. Risk of silent 
CD was especially high among first-degree relatives of CD patients who themselves had 
an AID diagnosis compared to those without such a diagnosis (25% vs 4.7%). This 
emphasizes that CD in combination with other AIDs is often asymptomatic and screening 
of risk populations has been recommended [200].  
The data on whether or not undiagnosed CD has adverse outcomes on glycemic 
control of T1D or on growth of the child are conflicting [238]. Untreated CD patients 
have an increased risk for iron deficiency anemia, growth retardation, osteoporosis, 
neuropsychiatric disorders, fertility problems, and intestinal lymphoma. Although data 
on long-term risk or benefit of gluten free diet on asymptomatic children diagnosed with 












Table 7. Frequency of CD and celiac autoimmunity in patients with T1D. 
 
Study population Country 





Celiac disease         
pediatric Israel  8.3 [189] 
all ages Belgium  2.3 [230] 
1-27 yrs Germany  1.7 [231] 
pediatric Australia 2.4  [183] 
pediatric Finland  4.7 [155] 
pediatric USA 2.9  [180] 
pediatric Greece  3.5 [232] 
pediatric Greece  4.8 [233] 
all ages international  2.7 [34] 
pediatric USA  2.3 [234] 
pediatric USA  1.8 [235] 
pediatric Finland  2.1 [236] 
pediatric Sweden 3.3 10  [182] 
pediatric Finland 1.2 2.4 [181] 
pediatric Italy 3.6 6.2 [228] 
0.8-22.4 yrs UK  0.5 [237] 
5-35 yrs Israel 0.1-1.3 5.5 [238] 
pediatric Algeria  16.4 [239] 
all ages Italy 5.0  [240] 
pediatric Italy  7.6 [185] 
not pediatric Italy 0.6 5.7 [241] 
pediatric Israel  4.0 [242] 
pediatric Sweden  6.7 [229] 
pediatric Australia  4.2 [243] 
pediatric Estonia  3.3 [244] 
Anti-tTG         
1-27 yrs Germany  4.4 [231] 
pediatric USA  11.6 [235] 
<30 yrs Germany/Austria  10.7 [245] 
pediatric USA 11.6  [180] 
pediatric Greece  7.6 [232] 
pediatric Greece 5.7 8.6 [233] 
pediatric USA  10.1 [234] 
partly pediatric Germany 3.9  [246] 
mostly pediatric Italy 8  [247] 
mostly pediatric Germany 16.8   [248] 
0.8-22.4 yrs UK 25 13.4 [237] 
partly pediatric Germany 10.1  [249] 
pediatric Italy  15.1 [240] 
pediatric Israel  6.5 [242] 
EMA         
pediatric Australia 2.4  [183] 
pediatric Italy 5.5  9.9 [228] 
all ages USA  4.4 [250] 
all ages Italy   5.7 [241] 
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Pathogenesis and etiology of celiac disease 
The strongest CD risk haplotype is HLA-DR3-DQ2. This haplotype is evident in 
approximately 90% of children with CD and 55% of children with T1D [220], compared 
to 20 to 25% of the general population. Somewhat lower figures have been reported in 
Finland, suggested to partly explain the lower prevalences of CD in patients with T1D 
[236]. The DR3-DQ2 haplotype exerts CD risk in an additive manner, with homozygotes 
at highest risk [251]. 
Not everyone with the susceptible HLA haplotype develop CD, however, which 
highlights the importance of environmental factors. The timing of introduction of gluten 
and breast feeding during this introduction have been suggested to be related to CD risk. 
The epidemic of CD in Sweden during the 80’s coincided with greater gluten 
consumption after 6 months of age [252]. Recent randomized, controlled trials have not 
confirmed these findigs, however. A European multicenter study (PreventCD) [253] and 
an Italian study [254] detected no effect of timing to gluten introduction (4-6months or 6 
months vs. 12 months of age). Breast feeding, neither exclusive nor during gluten 
introduction, influenced later development of CD. Other environmental risk factors 
related to CD are elective cesarean section, perinatal and childhood infections, and the 
use of antibiotics and proton-pump inhibitors [255, 256]. 
Female gender is a risk a factor for CD [251], although not evident in all populations 
[250]. For CD in T1D, reports both for and agaist increased risk in female patients exists. 
In Italy and Estonia, more girls have been reported with the double diagnosis [240, 244, 
257, 258], whereas in Sweden and Autralia both genders have been affected equally [182, 
229, 243]. Additionally, young age at diagnosis of T1D, first-degree relatives with AIDs, 
IA-2A negativity, and HLA-DR3-DQ2 have been associated with risk of CD in patients 
with T1D (Table 5).  
Comorbid AIDs related to CD are usually diagnosed before the diagnosis of CD. In 
T1D, most CD cases are diagnosed within two years after T1D diagnosis. It has been 
speculated that the metabolic derangement at diagnosis of T1D could accelerate the 
autoimmune process related to CD and thus lead to increased incidence of CD after T1D 
diagnosis [182]. Also, it has been hypothesized that continuing gluten exposure in silent 
CD might increase the risk for other AIDs [259].  
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Heterogeneity within T1D 
As knowledge of the T1D disease process has accumulated, we have come to understand 
that T1D is characterized by considerable heterogeneity. The genetic etiology, timing of 
autoantibody appearance, large range in age at onset of the disease, and the highly 
variable length of the prediabetic process highlight the variability seen in the disease. 
This heterogeneity could reflect various pathogenetic mechanisms of T1D. In fact, 
differential disease processes have been proposed for example depending on the first 
autoantibody to appear during the prediabetic disease process: IAA as the first 
autoantibody associates with INS risk genotype, PTPN22 risk genotype, HLA-DR4-DQ8, 
and early age at seroconversion. In contrast, GADA as the primary autoantigen develops 
later and in children with HLA-DR3-DQ2 [25-27]. In Finnish data, IKZF4-ERBB3 was 
associated with the progression of T1D after development of islet autoimmunity only in 
subjects with GADA as their first antibody, whereas INS associated with seroconversion 
only in children with IAA as the first autoantibody [104]. These pathogenetic pathways 
with different first autoantibodies could possibly operate together with a synergistic 
effect. This hypothesis is supported with the enhanced genetic risk associated with HLA-
DR3-DQ2/DR4-DQ8 heterozygosity. 
The different pathogenetic pathways could possibly be initiated or promoted through 
different etiological triggers. In fact, such gene-environment interactions have been 
described. For example, the PTPN22 gene polymorphism affects the rate of diabetes-
associated autoimmunity and clinical disease only in children who were introduced to 
cow´s milk based infant formula before the age of six months [260]. Cesarean section 
increases T1D risk only in children with high risk IFIH1 genotypes [112]. Examples of 
gene-gene interactions include the increased risk effect of PTPN22 in those negative for 
DR3-DQ2/DR4-DQ8 genotype [25, 75, 261] and a stronger protective effect of CTLA-4 
in those with DR4-DQ8/nonDR3-DQ2 or DR3-DQ2/nonDR4-DQ8 [75].  
Heterogeneity in genetics has been described according to age at onset. Risk alleles 
in IL2 and RNLS genes have been associated with younger age at onset [75] and 
rs10517086 has been associated with islet autoimmunity in those children under the age 
of 2 years [262]. Also, disease variants characterized by the rate of progression to T1D 
have been described. In a German study, the children progressing rapidly (<3years) from 
islet autoimmunity to clinical T1D were distinguished from slow progressors by an 
overall higher genetic load of alleles predisposing to T1D. The development of IA-2A in 
slow progressors was delayed, and rapid progressors were delivered by cesarean section 
[41]. 
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Different pathogenetic mechanisms of T1D have also been suggested in isolated T1D 
and in T1D associated with a broader autoimmune activation reflected by multiple AIDs 
[230, 263]. The double diagnosis of T1D and CD has been associated with two non-HLA 
loci, viz. CTLA4 and IL2RA [187]. 
This kind of subtyping of the disease helps us to understand the pathogenetic 
mechanisms and natural course of the disease, eventually making it possible to identify 
means for prediction and prevention of the disease, which might depend on the disease 
subtype.  
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Aims of the study 
This thesis is focused on determining the frequency of additional autoimmunity in 
Finnish children newly diagnosed with T1D and in their extended family members, and 
characterizing the effects of this additional autoimmunity on clinical, metabolic, and 
genetic markers as well as T1D related autoantibodies. 
The specific aims of this thesis were: 
 
1. To collect current data for frequencies of additional AIDs among Finnish children 
under the age of 15 with newly diagnosed T1D and the frequencies of T1D and 
other AIDs in their extended family. 
 
2. To compare children with familial and sporadic T1D in terms of T1D related 
autoantibodies as well as clinical, metabolic, and HLA class II genetic markers: 
A stronger genetic susceptibility to T1D and a milder metabolic decompensation 
in children with a positive family history for T1D was expected, whereas no 
differences were predicted in the autoantibody profile. 
 
3. To compare children with personal or family history of AIDs other than T1D in 
terms of T1D related autoantibodies as well as clinical, metabolic, and HLA class 
II genetic markers: These children were expected to have an increased prevalence 
of DR3-DQ2 and a stronger autoimmune reactivity against beta cell antigens 
manifested as more frequent autoantibodies with higher titers. The rationale 
being that, if the immune system is broadly active as evident by multiple AIDs 
in the patient or their family members, it could be assumed to be broadly active 
also against autoantigens of one disease. 
 
4. To characterize T1D co-occurring with CD or CD related autoimmunity: 
overrepresentation of HLA-DR3-DQ2 positives and a broader β-cell-specific 
autoimmunity were expected. 
 
5. To evaluate the effect of non-HLA gene loci on clustering of autoimmunity in 
individuals and families with T1D. 
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Subjects and methods 
Study subjects 
All the subjects of this thesis were participants of the Finnish Pediatric Diabetes Register 
and Sample Repository. This is a nation-wide project initiated in 2002 to study childhood 
diabetes in Finland. All children diagnosed with diabetes in Finland and their families are 
invited to participate by the hospitals handling the T1D diagnosis. The Register includes 
a questionnaire (Supplement of Study I) with questions on the family structure, diseases 
of the child and family members, as well as clinical markers at diagnosis of the child 
(blood glucose, pH, duration of diabetes symptoms, etc.). The index children and their 
first-degree relatives (mothers, fathers, siblings) are asked to give blood samples to the 
Sample Repository. The samples are analyzed for islet autoantibodies (ICA, IAA, 
GADA, IA-2A, ZnT8) and HLA class II DR- and DQ-haplotypes. The T1D risk mediated 
by these haplotypes is classified into risk classes. The Register does not include 
systematic follow-up of the cases, but if an additional member of the family is diagnosed 
with diabetes in a participating pediatric center and registered, the family information is 
updated accordingly. 
In 2009, the coverage of the Register was investigated over a three-year period by 
asking pediatric hospitals to record all the patients diagnosed at their center and 
comparing this information on that found in the Register. The proportion of newly 
diagnosed children registered was 92% [264]. Approximately 70% of those registered 
give samples for the Sample Repository. 
Study I and II 
For studies I (Familial T1D) and II (Other AIDs), data on 1488 children were collected 
from the Register. The median age at diagnosis of T1D was 8.2 years, 56.9% of the 
subjects were male. At data collection in October 2006, the Register included 2662 
children with T1D. Children diagnosed at 15 years of age or later, with no information 
on any relatives in the Register, or incomplete autoantibody analyses were excluded. Sex 
distribution or the median age of those included and excluded did not differ. 
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For the study III (CD autoimmunity), we compiled a series of 745 families with blood 
samples available from mother, father, at least one sibling, and an index child diagnosed 
with T1D before the age of 15. At the time of data collection in August 2007, the Register 
included a total of 2758 index children (median age at diagnosis 8.2 years, 56.1% male). 
The 745 index children who fulfilled the inclusion criteria were diagnosed at a median 
age of 8.8 (range 0.8-14.99) years and 56.6% were boys. In addition, we included 745 
mothers (median age 38.3 years), 745 fathers (median age 40.5 years), and 1202 siblings 
(median age 9.7 years, 49.8% male) of the index children. Thus, the total number of study 
subjects was 3437. 
Study IV 
For the study IV (HLA and non-HLA genetics) we included children with genotyping 
data available for non-HLA loci. The genotyping was originally performed for a study 
involving trio families with samples from both parents and one affected child diagnosed 
with T1D under the age of 15 years [265]. Of these children, 1784 were included in the 
study IV. The median age at diagnosis was 7.9 years and 57% were male. During quality 
control, however, 39 individuals failed the missingness tests (genotyping call rate of at 
least 50%). The number of study subject for the final analysis was thus reduced to 1745. 
Pooling of the study subjects 
For the data presented in this thesis book, the study subjects included in different studies 
were pooled together. In addition to the 1488 children included in studies I and II, 40 
children included only in study III and 726 children included only in study IV were added. 
One child was excluded since maturity onset diabetes of the young (MODY) was 
discovered in the family after the inclusion in the original study. Eight children were 
excluded because only one child per family was allowed in the study population. In 
general, the sibling included in study III was included, since this is the study with the 
most follow-up data collected from the family. Finally, this totaled 2245 index children 
with T1D diagnosed between January 2002 and November 2009. This time period 
coincides with the peak incidence of T1D in Finnish children [7]. If we assume 500-550 
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new cases of pediatric T1D in Finland annually, this thesis includes 51-56% of all 
children diagnosed during this time period. The majority were boys (n=1283, 57.1%) and 
the mean age at diagnosis of T1D was 7.9 years (median 8.1, range 0.28-15.0). 
Methods 
Determining family history of autoimmune diseases 
Data from the structured questionnaires of the Register were the basis of family 
information on all studies. Diabetes of first-degree family members and grandparents was 
available from the structured part of the questionnaire, and information on other diseases 
and other relatives was manually coded from open answers. The extra information 
provided by the family varied from none to an extra sheet of paper. All this data was read 
and coded accordingly. For example, diabetes described to have developed after growth 
hormone and glucocorticoid therapy in the absence of islet autoantibodies was re-
classified as other diabetes.  
For studies I and II, only the first child registered in the Finnish Diabetes Register 
was included and all possible additional information provided by the the questionnaires 
of the successive family members diagnosed and registered after the diagnosis of the 
index case were omitted. Accordingly, these studies represent the situation at the time of 
T1D diagnosis. 
In study III, data from the questionnaires was used to determine the frequency of 
known CD diagnoses at T1D diagnosis of the index children. To include as much follow-
up data as possible, the prevalence of known CD and hypothyreosis diagnoses by April 
2012 [median 7.7 (range 5.1-10.2) years after the T1D diagnosis of the index case] was 
based on data from the Social Insurance Institution of Finland. We obtained data for all 
3437 study subjects on right for medicine expenses reimbursement due to hypothyreosis, 
right for dietary reimbursement due to CD, and right for disability allowance due to CD. 
Since this registration is a requirement for financial benefits, we assumed that most 
diagnoses were included. However, a child receiving disability allowance due to T1D 
will not qualify for additional benefits if diagnosed with CD. Accordingly, these new CD 
diagnoses might not have been recorded to the Social Insurance Institution. For this 
reason, the patient records were checked for children with T1D but without known CD 
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diagnosis. The subjects with high anti-tTG and/or EMA in our assays, were 
contacted/attempted to contact by local hospitals to offer current autoantibody testing 
and/or duodenal biopsy to diagnose CD.  
In study IV, we included all available data on diseases of the index child and family 
members after the above mentioned methods of ascertainment. Additionally, for 42 
children, more information on diseases of the family were acquired from the 
questionnaires filled in when an additional family member was diagnosed with diabetes 
and registered. 
Thus when pooled together, around 800 of the 2245 children (36%) had follow-up 
data collected at a median of eight years after the diagnosis of the index case.   
As data for other AIDs was collected with open questions in the questionnaire, the 
families used their own words to name the diseases of the family. The AIDs were grouped 
for data handling and analysis under autoimmune thyroid disease (hypothyreosis, 
hyperthyreosis of autoimmune origin), CD (CD and dermatitis herpetiformis), 
rheumatoid diseases and other AIDs. Rheumatoid diseases included e.g. rheumatoid 
arthritis, ankylosing spondylitis, systemic lupus erythematosus, Sjögren’s syndrome, 
mixed connective tissue disease, scleroderma, collagenosis NAS, psoriatic arthritis, and 
polymyalgia rheumatica. Other AIDs included e.g. psoriasis, MS, pernicious anemia, 
adrenal dysfunction, inflammatory bowel diseases (Crohn’s disease and ulcerative 
colitis), vitiligo, alopecia, iritis, Wegener’s granulomatosis, and myasthenia gravis. 
All available information was used for analyses (number of cases with missing 
information presented in Table 8). Missing information on diabetes status was 
structurally recorded in the questionnaire for first-degree relatives and grandparents. This 
data was taken into account when calculating for example prevalences of T1D in different 
relative groups in study I. When creating comparison groups, e.g. familial vs. sporadic 
T1D, the children with missing information on some relatives, and no T1D reported in 
any other relatives, were counted as sporadic cases. For the pooled analyses in this thesis 
book, however, this missing information was not accounted for. The rationale was to 
make the data easily comparable with that on studies II-IV. The differences in 
prevalences with or without missing information is at maximum two tenths of a percent. 
The information on other AIDs, however, was not collected structurally, and accordingly, 
we have no systematic information on those relatives with unkown disease status. Thus, 
all relatives not reported to specifically have a diagnosis of an AID in the questionnaire, 
were counted as not having any AIDs. 
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Grouping of cases 
In study I, children with familial T1D were compared to sporadic cases. Familial cases 
were further subdivided to those with affected first-degree relatives (mother, father, 
sibling), second-degree relatives (grandparents, siblings of parents), or both. 
In study II, the children who themselves had another AID in addition to T1D were 
compared to children with T1D only. The children with family history for other AIDs 
(those with family history for T1D excluded) were compared to a group of children with 
T1D only and without any first- or second-degree relatives with T1D or other AIDs. A 
classification of children to so called autoimmune families was also used. An 
autoimmune family was defined as more than three (≥4) diagnoses of AIDs (T1D or 
other) and/or more than two (≥3) different AIDs (T1D or other) in first- and/or second-
degree relatives and/or the index child. This definition was elected to enable analysis of 
families were autoimmunity was truly clustered when at the same time ensuring adequate 
group size for statistical analysis. Thus, for the comparison of family history of other 
AIDs, the effect of familial T1D is completely excluded as these children are excluded 
from both comparison groups. In contrast, the comparison of autoimmune families 
studies differences between families with clustered autoimmunity for T1D or other AIDs. 
In study III, children with CD and children with anti-tTG were compared to children 
without CD or anti-tTG. Similarly, first-degree relatives of children with T1D with CD 
and with anti-tTG were compared to relatives without CD or anti-tTG. 
 In study IV, genetic determinants were assessed between children with addional 
AIDs and children with T1D only, as well as children from autoimmune families and 
children with T1D only and without any family history of T1D or other AIDs. 
When pooled together for this thesis, the compared groups were changed somewhat. 
Children with different forms of familial T1D or family history of other AIDs were both 
compared to a group of children with T1D only and without any family history for T1D 
or other AIDs (n=1089). This is in contrast to study I, in which familial cases were 
compared to cases without family history of T1D regardless of the family history for 
other AIDs. Children with additional autoimmune diseases were compared to children 
with T1D only and without anti-tTG (n=2152). 
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Table 8. Number of cases with missing data according to variables used in the 








Sex 0   
Age at diagnosis of the index child 1 755 723 
Days from diagnosis at sample 5   
Number of children in the family 3   
Number of children with diabetes in the family 25   
Birth order of the index child 8   
First affected child of the family 24   
All data on diabetes of the core family missing 19   
Diabetes data of the father 58   
Diabetes data of the mother 31   
Diabetes data of the siblings 27   
Diabetes data of brothers 28   
Diabetes data of sisters 28   
Diabetes data of all grandparents 53   
Diabetes data on paternal relatives 35   
Diabetes data on maternal relatives 8   
Islet cell autoantibodies (ICA) 6   
Insulin autoantibodies (IAA) 7   
IA-2 autoantibodies (IA-2A) 7   
GAD autoantibodies (GADA) 7   
ZnT8 autoantibodies (ZnT8A) 333   
HLA risk group 14   
DR3-DQ2/DR4-DQ8 31   
DR3-DQ2/x* 28   
DR4-DQ8/y† 32   
x*/y† 22   
Protective genotype 24   
DR4-DQ8 positive 27   
DR3-DQ2 positive 28   
DR3-DQ2 homozygote 22   
DR4-DQ8 homozygote 23   
Blood glucose 34   
pH 61   
Betahydroxybutyrate 389   
Level of consciousness 96   
Duration of symptoms, days 1115   
Duration of symptoms, categorical 251   
Weight loss 10   
Height, cm 44   
Weight, kg 31   
BMI 46   
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IAA, GADA, IA-2A, and ZnT8A were analyzed using specific radiobinding assays [46, 
266-268]. The cut-off limits were 2.80, 5.36, 0.77, and 0.61 RU, respectively. These were 
determined as the 99th percentiles in Finnish non-diabetic children and adolescents. 
According to the 2010 Diabetes Autoantibody Standardization Program (DASP), the 
sensitivities of these assays were 50, 88, 64 and 60% and specificities 96, 94, 99 and 
100%. Islet cell antibodies (ICA) were analyzed with indirect immunofluorescense on 
human group 0 donor pancreas with 2.5 Juvenile Diabetes Foundation (JDF) units as the 
detection limit [17]. Only samples at or above the cut-off for antibody positivity were 
included when calculating the median antibody titers. Samples that were taken more than 
30 days after the diagnosis of T1D were excluded from the antibody analyses. 
In study III, all 3437 samples were analyzed for total- and IgA-specific anti-tTG. The 
radiobinding immune assay for total-anti-tTG is essentially like those for islet 
autoantibodies and measures mostly IgG isotype. The IgA-specific anti-tTG assay was 
similar to that described previously for isotype-specific β-cell autoantibodies [269]. The 
cut-off limit for total-anti-tTG positivity was 1.75 RU and for IgA-anti-tTG 1.56 RU, 
representing the 99th percentile in 216 healthy Finnish children and adolescents. 
According to the 2007 anti-tTG workshop, the disease sensitivity and specificity of the 
IgA-anti-tTG assays were 91% and 98%, respectively. To rule out IgA deficiency, the 
samples negative for IgA- but positive for total-anti-tTG were analyzed with a 
photometric, immunochemical method for total IgA levels in the Helsinki University 
Central Hospital Diagnostic Laboratory (HUSLAB). EMA were analyzed in Tartu with 
an immunofluorescence method described previously [270]. Cut-off for positivity was 
serum dilution 1:5. 
Markers of metabolic decompensation at diagnosis 
Blood pH, plasma glucose, and plasma beta-hydroxybutyrate levels of the index children 
were analyzed in local laboratories at diagnosis of T1D. 
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Analysis of HLA genotypes 
Polymerase chain reaction (PCR) amplification of gene segments followed by 
hybridization with lanthanide-labeled sequence-specific oligonucleotide probes using 
time resolved fluorometry for detection was used for HLA typing of major T1D risk DR-
DQ haplotypes [51]. At the time of analysis, a risk classification to five groups according 
to HLA class II genotyping results was used for the Register. Three groups represent 
those with an increased risk of T1D (risk over 1% by 15 years of age, groups 2-4), one 
group is neutral (riskgroup 1) and the last protects from T1D (riskgroup 0). 
Analysis of non-HLA genotypes 
The Sequenom (San Diego, California, USA) platform (Genome Center of Eastern 
Finland, University of Eastern Finland, Kuopio) was used for genotyping non-HLA SNPs 
in study IV. CCR5 delta-32 deletion (rs333) was genotyped using PCR with fluorescently 
labelled primers and automated sequencer. 
Statistical methods 
SPSS (Statistical Package for Social Sciences, SPSS Inc., Chicago, IL, USA) versions 
17.0 through 24 were used for the majority of the analyses. Differences in frequencies 
were evaluated with cross-tabulation and χ2 statistics with Yates continuity correction or 
Fisher exact test when appropriate. For evaluation of differences in continuous variables 
Student’s t-test or one way ANOVA were used for normally distributed variables, and 
Mann-Whitney U test/Wilcoxon’s rank sum test for two groups or Kruskal-Wallis test 
with Dunn’s post hoc test for over two groups of comparison for skewed distributions. 
Linear trend for variables with over two groups was tested with linear-by-linear test for 
categorical variables and Jonckheere-Terpsta test for continuous variables. For binary 
outcome variables logistic regression was used when adjusting for confounding factors 
and for continuous outcome variables with a skewed distribution quantile regression in 
R 12.2.1 package for statistical computing, package quantreg 4.54.  
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For study IV, association analysis with PLINK v1.07 software package 
(http://pngu.mgh.harvard.edu/purcell/plink/) [271] was used for testing allele 
associations with phenotypic traits. Power calculations for the discussion in Study IV 
were carried out with Quanto 1.2.4 (http://hydra.usc.edu/gxe, 2006) software. For 
multivariate analyses, standard regression models were built to assess the contribution of 
HLA and non-HLA genes. Generalized linear models with complementary log-log link 
functions and stepwise forward model selection to minimize Akaike’s information 
criterion were applied.  
A two tailed P-value of 0.05 or less determined statistical significance. In general, 
Bonferroni corrections were not applied due to their overly conservative nature. In study 
IV, the P values of association analyses were corrected for multiple comparisons by false 
discovery rate (FDR) step-up procedure described by Benjamini and Hochberg [272]. In 
general, the increased probability of falsely positive statistical tests from a large number 
of tests, was taken into account by cautious interpretation of the results. 
Ethics 
The ethics committee of the Hospital district of Helsinki and Uusimaa has approved the 
protocol of the Finnish Diabetes Register and Sample Repository as well as the ancillary 
study of related CD autoimmunity. All participants aged 10 to 17 years give their written 
assent for participation and the legal guardians of the children and all participants over 
the age of 18 years give their written informed consent at the time of registration. The 










For the 2245 index children, median number of days from the diagnosis to drawing of 
the blood sample was 5 (range -301-1385). Almost all children (98%) had at least one 
positive T1D related autoantibody. Median number of positive autoantibody responses 
was four out of five. According to the data provided to the Register, 439 (19.6%) children 
did not have any siblings. 
Frequency of autoimmune diseases 
Index children 
At diagnosis of T1D, 37 (1.6%) children had already been diagnosed with another AID. 
At the end of the study with a median of 8 years of follow-up, 71 (3.2%) had some 
additional AID (Table 9), and 34 (1.5%) had CD. Of the children with T1D only 
(n=2174), 701 children were included in study III and were thus analyzed for anti-tTG at 
diagnosis of T1D. Of these, 22 had anti-tTG. These children were excluded from the 
comparison group making the number of children in the group of no additional 
autoimmunity 2152. There was a trend for more AIDs in those children older at T1D 
diagnosis; prevalence of additional AIDs was 2.3% among 0-4-year-olds, 2.8% among 
5-9 year-olds, and 4.2% among 10-15 year-olds (P for trend=0.04). 
Of the 2245 children, 744 children were included in Study III (one child originally 
included in this study was excluded as MODY was discovered) and were analysed for 
anti-tTG at diagnosis of T1D and extensively investigated for the presence of CD. Of 
these 36/744 (4.8%) had anti-tTG. Of the anti-tTG positive, 36.1% (13/36) were also 
positive for EMA.  
CD at diagnosis of T1D was reported by 0.7% (5/744) of the index cases, and, after 
anti-tTG screening and search through registers of the Social Insurance Institution of 
Finland and patient records, 24 (3.2%) had CD. Interestingly, only 36% (13/36) of those 
with anti-tTG at diagnosis had developed CD by the final search [or 13 of the 24 CD 
patients (54%) had anti-tTG at diagnosis of T1D]. This means that 64% (23/36) of the 









follow-up of eight years, despite seven of these (7/23, 30%) having either high anti-tTG 
(≥10 times the upper limit of normal) or positive EMA. 
 
Table 9. Number of index children with other autoimmune diseases in addition to 
T1D at diabetes diagnosis and at the end of the study. *At diagnosis one child had both 
AIT and rheumatoid disease, and at the end of the study two more children had multiple 
diagnoses: one with AIT and CD, and another with CD and vitiligo. 
 
Disease At diagnosis of T1D At the end of study 




Rheumatoid disease 5 5 
Colitis ulcerosa 1 1 
Alopecia 2 2 
Vitiligo 1 1 
Two different 
diseases* 1 3 
Total 37/2245 (1.6%) 71/2245 (3.2%) 
Familial type 1 diabetes 
At diagnosis of T1D, 264 (11.8%) of the 2245 children had a first-degree relative with 
T1D. At the end of the study this figure had increased to 305 (13.6%) (Figures 1 and 2). 
Of these children, 27 (1.2%) had two affected first-degree relatives, two (0.1%) had three, 
and one had four (mother, father, two sisters). The number of affected fathers was 134 
(6.0%). The number of mothers with T1D was 73 (3.3%) at diagnosis, and one additional 
diagnosis was discovered by the end of the study: 74/2245 (3.3%). The number of 
affected brothers increased from 42 (42/2245, 1.9%) to 65 (2.9%), and affected sisters 
from 33 (1.5%) to 60 (2.7%) from diagnosis to the end of study. This increased the 
number of affected siblings from 72 (3.2%) to 122 (5.4%) (the gender of one affected 
sibling was not reported). In other words, of those 1803 children known to have siblings, 









number of affected siblings was three. Prevalence of T1D among the total of 3101 
siblings in the cohort, was 4.3% (132/3101). 
The frequency of affected second-degree relatives was the same at diagnosis and at 
the end of study; 281 (12.5%). The number of children with affected maternal second-
degree relatives was 156 (6.9%) and affected paternal relatives 138 (6.1%). The number 
of affected second-degree relatives ranged from zero to five. 
In total, 489 (21.8%) children had a relative with T1D at diagnosis of T1D, and at the 
end of study the number was 522 (23.3%). Fifty-six children (2.5%) had both a first- and 
second-degree relative affected at diagnosis, and at the end of the study, 64 (2.9%). The 
maximum number of affected relatives in the extended family at the end of the study was 
six. The total number of second-degree relatives is unknown. 
 
 
Figure 1. Proportions (%) of families who reported T1D in different relative groups. 











Figure 2.  Flowchart on familial T1D showing the number and proportion of the 
total 2245 children for children with T1D patients in different relative groups. *Gender 









Other autoimmune diseases 
At diagnosis of T1D, 307 (13.7%) index children had a first-degree relative affected with 
an AID other than T1D. At the end of study, this figure was 331 (14.7%; Figures 3 and 
4). More mothers than fathers had AIDs (Figure 4); at diagnosis 195 (8.7%) mothers had 
an AID compared to 72 (3.2%) fathers, and at the end of the study 223 (9.9%) mothers 
had an AID in contrast to 86 (3.8%) fathers. At diagnosis, 23 (1.0%) children reported 
having a sibling with an AID other than T1D, and at the end of study 40 (1.8%). Of those 
1803 children reported to have siblings, these figures translate to 1.2% and 2.2%, 
respectively. The prevalence of other AIDs was 1.4% (44/3101) of all 3101 siblings. 
For second-degree relatives the figures did not increase during the study period; 590 
(26.3%) children reported a second-degree relative with an AID other than T1D. In total, 
499 (22.2%) of families reported affected grandparents; 405 (18.0%) families had 
affected grandmothers, and 134 (6.0%) families affected grandfathers. Affected paternal 
second-degree relatives were reported by 282 (12.6%) families, and affected maternal 
second-degree relatives by 393 (17.5%) families. The total number of second-degree 
relatives is not known, which prevents us from reporting actual prevalences of diseases 
except for grandparents; the prevalence of AID other than T1D was 9.0% (405/4490) for 
grandmothers, 3.0% (134/4490) for grandfathers.  
In total, at diagnosis 760 (33.9%) and at the end of the study 804 (35.8%) index 
children had AID other than T1D in the extended family (first or second-degree relatives).  
 
At the end of the study, AIT in the extended family was reported by 432 (19.2%) 
families [at diagnosis 424 (18.9%)], CD by 177 (7.9%) families [at diagnosis 128 
(5.7%)], rheumatoid disease by 291 (13.0%) of families, and other AIDs by 107 (4.8%) 
of the families. These diseases were more common among second-degree than first-
degree relatives, with the exception of CD since first-degree relatives were specifically 
screened for this disease in study III (Figure 5).  The maximum number of first and/or 
second-degree relatives affected by AIT was 8, by CD was 4, by rheumatoid diseases was 
4, and by other AIDs was 3. In total, 270 (12.0%) children fulfilled the criteria for an 










Figure 3. Flowchart on familial clustering of autoimmune diseases other than T1D 
showing the number children and the proportion of the total 2245 children for children 
with affected relatives from different relative groups. †For two affected grandparents the 











Figure 4.  Proportions (%) of families who reported AIDs other than T1D in different 




The children with additional AIDs (n=71) or the children with extended family members 
with AIDs other than T1D (n=804), did not have relatives with T1D more often than 
children with T1D only (22.5 vs. 23.3%, NS) or children with no family history of 











Figure 5. Proportions of index children with relatives affected by AIDs in first- or 
second-degree relatives or both. AIT=autoimmune thyroiditis, CD = celiac disease. 
 
 
In total, 2689 first-degree relatives of 744 children were included in Study III (three 
relatives of the child later discovered to have MODY were excluded). Among these 
relatives, the prevalence of anti-tTG positivity in the sample at T1D diagnosis of the 
index child was 2.9% (79/2689); 4.8% (36/744) among the mothers, 2.4% (18/744) 
among the fathers and 2.1% (25/1201) among the siblings (Figure 2 in study III). Of the 
79 anti-tTG positives, 50 (63.3%) had also EMA. The respective proportions were 66.7% 
(24/37) for the mothers, 72.2% (13/18) for the fathers, and 52.0% (13/25) for the siblings. 
Only 0.6% (15/2689) of the relatives reported CD in the Register [1.1% (8/745) of the 
mothers, 0.5% (4/745) of the fathers, and 0.2% (3/1202) of the siblings]. By the end of 
case ascertainment, 2.5% (67/2689) had CD; 34 (4.4%) mothers, 16 (2.1%) fathers, and 
17 (1.4%) siblings (Figure 2 in study III). Of the 79 anti-tTG positive relatives, 48 
(60.1%) had CD by the end of data collection (or 48 of the 67 CD patients (72%) had 









anti-tTG positive relatives (33% of mothers, 28% of fathers, 56% of siblings) did not 
develop CD after eight years of follow-up, although 11 (35%, 11/31) of them had either 
high anti-tTG levels (≥10 times the upper limit of normal) or positive EMA. 
Characterizing familial type 1 diabetes 
Demographics 
The children with familial or sporadic T1D did not differ in terms of age at diagnosis or 
gender distribution (Study I, Table 10). The familial cases came from bigger families; the 
number of children in the family was higher, they were less often the only child, and the 
birth order of the child (first, second, third etc. child of the family) was higher. The size 
of the family relates to age at diagnosis, as the children who were the only child of the 
family were younger at diagnosis (median 5.8 vs. 8.6 years yrs, P<0.001).  
The frequency of familial T1D did not differ according to age groups; affected 
relatives in extended family were reported in 14.8% of 0-5-year-olds, 13.9% of 5-10-
year-olds, and 13.6% of 10-15-year-olds, P=0.81. Girls with maternal second-degree 
relatives with T1D were younger than girls with paternal second-degree relatives with 










Table 10. Demographics, markers of metabolic decompensation at diagnosis, 
autoantibodies, and HLA class II genetics of children with extended family members 
(first- and/or second-degree relatives) affected with T1D (familial T1D) compared to 




I. Familial T1D 
(n=522) 
II. No additional AID 
in family (n=1089) 
P 
value 
Demographics       
Sex, male, % 58.0 57.6 0.90 
Age at diagnosis, yrs, median 
(range) 
7.61 (0.28-14.95) 8.32 (0.69-15.0) 0.09 
Number of children in the family, 
median (mean) 
2 (2.6) 2 (2.3) <0.001 
Only child, % 16.3 23.3 0.002 
Birth order, median (mean) 2 (1.9) 1 (1.7) 0.004 
Number of days from diagnosis at 
sample, median 
5 5 0.40 
Metabolic decompensation at diagnosis     
Blood glucose, mmol/l, median 
(range) 
22.9 (3.6-97.6) 25.0 (4.9-92.7) <0.001 
Ketoacidosis, % 9.8 20.7 <0.001 
pH, median (range) 7.39 (6.80-7.54) 7.37 (6.84-7.52) <0.001 
ß-hydroxybutyrate, mmol/l, 
median (range) 
0.9 (0-20.1) 2.1 (0-16.2) <0.001 
Impaired consciousness, % 2.2 6.0 0.002 
Duration of symptoms, days, 
median (range) 
7 (0-332) 9 (0-314) 0.24 
Weight loss, kg, median, (range) 0.60 (0-15.0) 1.5 (0-17.0) <0.001 
BMI (range) 15.8 (11.1-32.7) 15.5 (11.0-32.7) 0.005 
Autoantibodies       
ICA, %  90.2 93.5 0.03 
ICA, JDFU, median (range) 40 (3-1,517) 40 (3-39,935) 0.42 
IAA, % 44.0 42.1 0.52 
IAA, RU, median (range) 10.7 (3.0-282.1) 10.3 (2.9-386.1) 0.76 
IA-2A, %   73.8 75.0 0.65 
IA-2A, RU, median (range) 103.3 (1.2-256.4) 101.9 (0.86-501.0) 0.09 
GADA, %  65.6 67.2 0.57 
GADA, RU,  median (range) 36.3 (5.4-1,699.2) 36.2 (5.6-324.7) 0.38 
ZnT8A, % 62.4 62.9 0.92 
ZnT8A, RU, median (range) 5.9 (0.6-200.3) 6.4 (0.6-459.4) 0.38 
Positive antibody responses, 
median (mean) 











I. Familial T1D 
(n=522) 
II. No additional AID 
in family (n=1089) 
P 
value 
HLA class II genetics       
DR3-DQ2/DR4-DQ8, %  22.8 20.7 0.38 
DR3-DQ2/x*, %  13.1 15.6 0.22 
DR4-DQ8/y†, %  51.7 46.8 0.07 
x*/y†, % 12.2 16.6 0.03 
Protective genotype, % 2.5 3.4 0.40 
DR3-DQ2 positive, %  36.0 36.4 0.90 
DR4-DQ8 positive, %  74.7 67.7 0.006 
DR3-DQ2 homozygote, % 3.7 2.4 0.21 
DR4-DQ8 homozygote, % 10.8 5.8 <0.001 
 
 
Table 11. Age and HLA class II genetics in children with second-degree relatives 
with T1D from the maternal or paternal side of the family. *x≠DR4-DQ8 †y≠DR3-DQ2 
 
    Second-degree familial cases   




(n=143) P value 
Age at diagnosis, yrs, 
median (range) 
male 8.1 (1.5-15.0) 6.9 (0.8-14.7) 0.42 
female 8.1 (1.3-14.4) 6.4 (1.6-14.4) 0.04 
HLA class II genetics         
DR3-DQ2/DR4-DQ8, %  
male 9.1 30.0 0.003 
female 25.7 14.3 0.23 
DR3-DQ2/x*, %  
male 22.7 15.0 0.29 
female 11.4 2.4 0.15 
DR4-DQ8/y†, %  
male 53.0 47.0 0.55 
female 55.1 61.9 0.61 
x*/y†, % 
male 15.2 8.0 0.23 
female 7.2 21.4 0.06 
Protective genotype, % 
male 3.0 0 0.16 
female 0 4.8 0.14 
DR3-DQ2 positive, % 
male 31.8 45.0 0.12 
female 37.1 16.7 0.04 
DR4-DQ8 positive, % 
male 62.1 77.0 0.06 
female 81.2 76.2 0.70 
DR3-DQ2 homozygote, % 
male 3.0 3.0 1.00 
female 4.3 2.4 1.00 
DR4-DQ8 homozygote, % 
male 7.6 9.0 0.97 










There were gender differences among the cases in terms of who in the family had 
type 1 diabetes (Study I, Table 12). In general, boys and girls had equally often relatives 
affected with T1D, and for first-degree relatives there were no differences. For second-
degree relatives, however, boys had more often affected relatives from the maternal side 
and girls from the paternal side.   
 
Table 12. Comparison of frequency of reporting T1D in different relative groups 
between boys and girls. The data are percentages (%) of the total number of male/female 
cases with information provided for the relative in question. 
 






Any relative 23.6 22.8 0.67 
First-degree relative 13.6 13.6 1.00 
Father 6.1 6.2 0.94 
Mother 3.4 3.3 0.97 
Brother 2.3 3.2 0.66 
Sister 2.7 2.7 1.00 
Second-degree relative 13.0 11.9 0.45 
Paternal grandparent 1.8 4.0 0.004 
Father's father 1.0 1.9 0.13 
Father's mother 0.8 2.1 0.02 
Maternal grandparent 3.7 2.3 0.09 
Mother's father 2.4 1.3 0.10 
Mother's mother 1.4 1.0 0.51 
Sibling of father 3.7 4.1 0.70 
Sibling of mother 5.0 3.3 0.07 
Paternal second-degree 5.2 7.6 0.03 
Maternal second-degree 8.1 5.4 0.02 
 
Autoantibodies 
Children with familial T1D were less often positive for ICA compared to children with 
sporadic T1D (Tables 10 and 13). This finding did not reach statistical significance in 









relatives with T1D tended to have lower number of positive autoantibody responses 
(Table 13). 
There were no differences in autoantibody profile in children from multigenerational 
families (parents with T1D) compared to children from multiplex families (siblings with 
T1D), or in children with T1D in maternal compared to paternal second-degree relatives.  
HLA class II genetics 
As observed in Study I, children with familial T1D had more often the HLA DR4-DQ8 
haplotype compared to children without family history for AIDs (Table 10). In contrast 
to Study I, which had a smaller sample size and analyzed data only from the time of T1D 
diagnosis of the index case, the children with familial T1D at the end of study had also 
less often a genotype without either of the risk haplotypes (nonDR3-DQ2/nonDR4-DQ8) 
and were more often homozygous for DR4-DQ8. Especially the children with affected 
relatives in both first- and second-degree relatives (Table 13) and the children with two 
or more affected relatives (Table 14) had a conspicuously high frequency of DR4-DQ8 
homozygozity. 
Children form multigenerational of multiplex families did not differ in terms of HLA 
class II genetics. Children with affected second-degree relatives from maternal or 
paternal side of the family were compared separately for each sex (Table 11); girls with 
affected paternal second-degree relatives had more often the risk haplotype DR3-DQ2 
and boys with maternal second-degree relatives the risk genotype DR3-DQ2/DR4-DQ8. 
A similar finding was reported in Study I, although statistical significance was reached 
for different haplotypes/genotypes. This finding concurs with the finding of more boys 









Table 13. Comparison of children with first-degree, second-degree, or both 
relatives affected with T1D compared to children with no family history of AIDs. P-values 
for comparison of the four groups together are shown. For significant P-values in these 
comparisons, subgroup analyses with Dunn’s post-hoc test were carried out and 
significant P-values are shown. P-value for trend (sporadic, first degree, second-degree, 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 14. Comparison of demographics, autoantibodies and HLA class II 
genetics in children with two or more T1D patients in the extended family and children 
without family history of autoimmune diseases. *x≠DR4-DQ8 †y≠DR3-DQ2 
  
I. Two or more 
affected relatives 
(n=113) 
II. No additional AID 
in family (n=1089) 
P value 
Demographics       
Sex, male, % 57.5 57.6 1.00 
Age at diagnosis, yrs, 
median (range) 
8.25 (0.7-14.6) 8.32 (0.69-15.0) 0.36 
Autoantibodies       
ICA, % 87.0 93.5 0.03 
ICA, JDFU, median (range) 25 (3-759) 40 (3-39,935) 0.39 
IAA, % 36.0 42.1 0.29 
IAA, RU, median (range) 11.0 (3.2-190.7) 10.3 (2.9-386.1) 0.97 
IA-2A, % 69.0 75.0 0.23 
IA-2A, RU, median (range) 107.5 (1.9-203.3) 101.9 (0.86-501.0) 0.15 
GADA, % 62.0 67.2 0.34 
GADA, RU, median (range) 36.6 (5.4-267.1) 36.2 (5.6-324.7) 0.74 
ZnT8A, % 59.5 62.9 0.63 
ZnT8A, RU, median (range) 6.4 (0.7-165.0) 6.4 (0.6-459.4) 0.68 
Positive antibody 
responses, median (mean) 
3 (3.12) 4 (3.4) 0.05 
HLA class II genetics       
DR3-DQ2/DR4-DQ8, %  22.5 20.7 0.75 
DR3-DQ2/x*, %  14.4 15.6 0.85 
DR4-DQ8/y†, %  54.5 46.8 0.15 
x*/y†, % 8.2 16.6 0.03 
Protective genotype, % 1.8 3.4 0.52 
DR3-DQ2 positive, %  36.9 36.4 1.00 
DR4-DQ8 positive, %  77.3 67.7 0.051 
DR3-DQ2 homozygote, % 1.8 2.4 1.00 
DR4-DQ8 homozygote, % 17.1 5.8 <0.001 
 
Metabolic decompensation at diagnosis 
Children with familial T1D had a milder metabolic decompensation at diagnosis than 
children with no family history of autoimmune diseases (Study I, Tables 10 and 13); they 
had lower blood glucose level, higher pH, lower levels of β-hydroxybutyrate, lower 









BMI. Importantly, these differences were evident also in the group of children with only 
second-degree relatives with T1D (Study I, Table 13), indicating that it is not necessary 
for the other patient with T1D in the family to be from the immediate family. Those 
children with T1D in both first- and second-degree relatives (Table 13) seemed to have 
the best metabolic situation at diagnosis. The duration of symtoms was shorter in familial 
cases but the difference was not statistically significant. 
There were no marked differences between children with affected paternal or 
maternal second-degree relatives, or children with multigenerational or multiplex T1D. 
Characterizing T1D associated with other autoimmune 
diseases 
Index children with additional autoimmune diseases 
Demographics 
Children with additional autoimmune diseases (n=71) were compared to children with 
T1D only and no anti-tTG (n=2152). As celiac disease was specifically screened for in a 
subset of cases in the context of Study III, and other diseases were not, comparison with 
children with CD excluded was also carried out (37 children compared to 2152, Table 
15). Gender distribution did not differ significantly for either of these groups although 
there was a female majority in the groups of additional autoimmunity. The prevalence of 
additional autoimmune disease at the end of study was 4.0% among girls and 2.6% among 
boys (P=0.09). Children with AIDs other than CD were older at T1D diagnosis (Table 
15).  There was some tendency for more children with additional AIDs in the oldest age 
group; the prevalence was 2.3% among those diagnosed at 0-4 years of age, 2.8% among 
5-9-year-olds, and 4.2% among 10-15-year-olds (P=0.09). Children with T1D only were 
more often the only child of the family (Table 15). 
Autoantibodies 
ICA positivity was more common among children with T1D only than in children with 
any additional AID or children with other AID than CD (Table 15). This difference was 
also seen in Study II. In addition, at the end of study, children with T1D only had more 









than children with any additional AIDs. These differences disappeared, however, when 
children with CD were excluded (Table 15).  
HLA class II genetics 
In Study II, no differences in HLA class II genetics were evident between children with 
multiple AIDs or T1D only. At the end of study, with addition of many patients with CD 
and AIT, more genotypes and haplotypes differed between the groups; for children with 
any additional AID, clear overrepresentation of the DR3-DQ2 haplotype and 
underrepresentation of the DR4-DQ8 haplotype was evident (Table 15, Table 2 in study 
IV). When children with CD were excluded, children without either of these haplotypes 
and children with genotypes protective for T1D were overrepresented (Table 15).  
Metabolic decompensation at diagnosis 
In study II, with only children with known additional AID already at diagnosis of T1D 
included, evidence for milder metabolic decompensation (lower plasma glucose and β-
hydroxybutyrate levels, higher pH, longer duration of symptoms) in children with 
multiple AIDs was observed. At the end of study, with inclusion of children who 
developed additional AIDs during follow-up after T1D diagnosis, such differences were 
no longer evident. Only longer duration of symptoms in children with additional AIDs 









Table 15.  Demographics, markers of metabolic decompensation at T1D diagnosis, 
islet autoantibodies, and HLA class II genetics in children with any additional AIDs or 
additional AIDs other than CD compared to children with T1D only and no tissue 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Children with family history of autoimmune diseases other than 
T1D 
Demographics 
Children with extended family history of AIDs other than T1D and children coming from 
autoimmune families were compared to children without any additional family history 
for AIDs. There were no gender differences between these groups (Table 16) or between 
sexes in the frequencies of having relatives AIDs in any specific relative groups. The 
frequency of reporting extended family members with these diseases was similar in all 
age groups; 37.2% in the age group of 0-5 years, 36.2% in the age group of 5-10 years, 
and 34.3% in the age group of 10-15 years, (P=0.52). 
As expected, the children with positive family history for AID other than T1D and 
especially the children from autoimmune families came from larger families, i.e. the 
number of children in the family and birth order of the index child were higher, and the 
prevalence of being the only child lower in most groups compared (Table 16). Only when 
comparing children with mothers or fathers affected with AID other than T1D, this 
difference was not observed.  In autoimmune families, also the age of the parents was 
higher. 
Autoantibodies 
In study II, higher levels of ICA and IA-2A were seen in the children with relatives 
affected by AID compared to the children with no family history of AID. In contrast, at 
the end of study, higher frequencies of IAA positivity were seen in children with family 
history of AIDs and lower frequencies of ICA positivity among children from 
autoimmune families (Table 16).  
Children with mothers, fathers, or siblings affected with AID other than T1D or 
children with family history specifically for AIT compared to children with no family 
history for AIDs did not differ in terms of islet autoantibody profiles. The children with 
rheumatoid diseases in the extended family had higher ICA (44 vs. 40 JDF units, P=0.04) 
and IA-2A levels (109.1 vs. 101.9 RU, P=0.02) as well as were more often positive for 
IAA (51.4 vs. 42.1%, P=0.01). 
HLA class II genetics 
There were no differences in HLA class II genetics in the children with or without a 









Children with mothers, fathers or siblings with AIDs other than T1D or chidren with 
relatives with AIT did not differ in terms of HLA class II genetics. However, the children 
with a positive family history for rheumatoid diseases carried less often the DR3-
DQ2/nonDR4-DQ8 genotype (9.7 vs. 15.6%, P=0.03). 
Metabolic decompensation at diagnosis 
As discovered already in Study II, the children with or without family history for AIDs 
other than T1D did not differ in terms of markers of metabolic decompensation at 
diagnosis (Table 16).  Children from autoimmune families, however, displayed a clearly 
milder metabolic decompensation at diagnosis (Table 16), which is probably due to the 
cases of familial T1D included in this group.  
The children who had relatives with AIT had lower levels of β-hydroxybuturate (1.6 
vs. 2.1 mmol/l, P=0.02) and higher pH (7.38 vs. 7.37, P=0.02) compared to the children 
without any family history of AID. Children with mothers, fathers or siblings with AIDs 
other than T1D, or children with family history of rheumatoid diseases did not differ in 










Table 16. Demographics, markers of metabolic decompensation at T1D diagnosis, 
islet autoantibodies, and HLA class II genetics in children with family history for 
autoimmune diseases (AID) other than T1D (I) or children from autoimmune families (II) 




with AID other 
















I vs. III: 
P value 
II vs. III: 
P value 
Demographics 
     
Sex, male, % 56.6 55.6 57.6 0.73 0.60 









Age of father at 









Age of mother at 









Only child, % 16.9 11.5 23.3 0.003 <0.001 
Number of children in 
the family, median 
(mean) 
2 (2.40) 2 (2.64) 2 (2.26) 0.001 <0.001 
Birth order of the index, 
median (mean) 
2 (1.85) 2 (2.05) 2 (1.72) 0.002 <0.001 
Days from diagnosis at 
sample, median 
5 5 5 0.91 0.27 
Metabolic decompensation at 
diagnosis 
    




23.2 (3.2-63.7) 25.0 (4.9-
92.7) 
0.16 <0.001 
Ketoacidosis, % 17.4 15.4 20.7 0.11 0.06 








mmol/l, median (range) 
1.8 (0-15.2) 1.4 (0-17.4) 2.1 (0-16.2) 0.10 <0.001 
Impaired 
consciousness, % 
4.6 2.3 6.0 0.26 0.03 
Duration of symptoms, 
days, median (range) 
12 (0-377) 8.5 (0-143) 9 (0-314) 0.10 0.49 
Weight loss, kg, median 
(range) 
1.5 (0-20.0) 1.0 (0-13.0) 1.5 (0-17.0) 0.65 0.003 

















I. Children with 





















     
ICA, % 93.9 88.3 93.5 0.85 0.007 
ICA, JDFU, median 
(range) 
44 (2.5-640) 40 (3-640) 40 (3-39,935) 0.07 0.38 
IAA, % 47.5 43.4 42.1 0.04 0.76 
IAA, RU, median 
(range) 
9.7 (2.9-414.2) 12.4 (2.9-239.8) 10.3 (2.9-
386.1) 
0.27 0.26 
IA-2A, % 78.8 72.3 75.0 0.10 0.41 









GADA, % 69.1 71.9 67.2 0.48 0.18 









ZnT8A, % 61.0 59.8 62.9 0.52 0.45 
ZnT8A, RU, median 
(range) 
7.2 (0.6-308.9) 5.9 (0.7-298.8) 6.4 (0.6-459.4) 0.42 0.19 
Number of positive 
antibodies, median 
(mean) 
4 (3.5) 4 (3.3) 4 (3.4) 0.35 0.36 
HLA class II genetics 
     
DR3-DQ2/DR4-DQ8, % 22.9 23.1 20.7 0.33 0.44 
DR3-DQ2/x*, % 14.1 15.3 15.6 0.45 0.98 
DR4-DQ8/y†, % 47.7 47.6 46.8 0.78 0.88 
x*/y†, % 15.3 13.9 16.6 0.53 0.33 
Protective genotype, % 4.1 3.4 3.4 0.55 1.00 
DR3-DQ2 positive, % 37.0 38.4 36.4 0.85 0.59 
DR4-DQ8 positive, % 70.6 70.8 67.7 0.24 0.37 
DR3-DQ2 homozygote, 
% 
3.3 3.0 2.4 0.35 0.75 
DR4-DQ8 homozygote, 
% 
6.5 9.0 5.8 0.64 0.08 
Characterizing type 1 diabetes associated with celiac 
disease 
Demographics 
By the end of data collection in Study III, 24 children of the 744 children included were 
diagnosed with CD. When including the additional children with known CD in the 
Register, there were 34 (1.5%) children with CD among the 2245 index children. Neither 









positive anti-tTG at T1D diagnosis (Table 1 in study III) differed from the children 
without CD or anti-tTG in terms of age at diagnosis or gender. Children with CD were 
less often the only child of the family. This is in accord with the fact that Study III with 
a search for silent CD had an inclusion criterium of at least one sibling with sample in 
the Sample repository.  
The 79 anti-tTG positive first-degree relatives and the 67 first-degree relatives with 
CD (Table 2 in study III) were older and more often female than the relatives without 
anti-tTG or CD. There was also a tendency for having a diagnosis of an AID other than 
CD or T1D more frequently. 
The median levels of total- or IgA-anti-tTG did not differ between the index children, 
mothers, fathers or siblings (data not shown), and neither did the proportion of those with 
high levels in either isotype among the anti-tTG positives (index children 44.4%, mothers 
63.9%, fathers 55.6%, sibling 48.0%, P=0.38). Anti-tTG positivity not developing into 
CD during follow-up, however, was more common among the index children than first-
degree relatives (63.9% vs. 39.2%, P=0.01). In general, those who developed CD had 
higher levels of both anti-tTG isotypes compared to those without CD; IgA-anti-tTG: 
66.3 vs. 3.9 RU (P<0.001), total-anti-tTG: 10.7 vs. 4.6 RU (P<0.001). However, among 
those without CD but positive for anti-tTG, total-anti-tTG levels tended to be higher 
among index children (median in index children 6.9RU, mothers 4.0RU, fathers 4.4RU, 
siblings 3.4RU, P=0.049), but IgA-anti-tTG did not (index children 3.8RU, mothers 
4.0RU, fathers 4.3RU, siblings 5.0RU, P=0.86). Anti-tTG positivity not leading to CD, 
was not limited to either total or IgA specific assay; 81.5% (44/54) of those positive for 
anti-tTG but without CD had total-anti-tTG and 70.4% (38/54) had IgA-anti-tTG. High 
total-anti-tTG levels were observed in four cases (7.4%) and high IgA-anti-tTG in 12 
(14.8%). These proportions did not differ between index children, mothers, fathers or 
siblings. Accordingly, these findings do not support the hypothesis that lower levels of 
anti-tTG or antibody isotype profiles explained the higher frequency of benign anti-tTG 
positivity in index children. 
Autoantibodies 
Index children positive or negative for anti-tTG did not differ in terms of islet 
autoantibody profile (Table 1 in study III). The children with CD (Table 15 and Study 
III), however, tended to have lower levels of ZnT8A and less often IA-2A compared to 
children without anti-tTG or CD. Moreover, their overall number of positive islet cell 









First-degree relatives with anti-tTG were more often positive for GADA, whereas 
there were no differences between relatives with CD and those without CD autoimmunity 
(Study III). 
HLA class II genetics 
The association of anti-tTG positivity and especially CD with HLA-DR3-DQ2 was clear-
cut in both index children and first-degree relatives (Table 15 and Study III). OR for CD 
for this haplotype was 8.4 and for anti-tTG positivity 5.0. Of the children with both T1D 
and CD, 79% carried this haplotype, and of the first-degree relatives with CD, 73%. 
Homozygozity for this haplotype was observed in 21% of index children and 8% of the 
relatives with CD. As this population was patients or first-degree family members with 
T1D, the HLA-DR4-DQ8 was overrepresented in relation to other populations with CD. 
Only one index child and no relatives with CD, had neither of these two CD risk 
haplotypes.  
Metabolic decompensation 
There were no marked differences in markers of metabolic decompensation between 
children with anti-tTG or CD (Table 15 and Study III) and children without any additional 
autoimmunity; although there was some indication for lower weight loss or lower BMI 
in children with CD related autoimmunity. 
Non-HLA genes and clustered autoimmunity 
Association analyses 
Of the 2245 children, 1780 were included in Study IV, but only 1745 of them passed the 
quality control step of having at least half of the tested polymorphisms genotyped 
successfully. Of these 1745 children, 60 (3.4%) had another AID in addition to T1D by 
the end of study. When association analyses for 41 SNPs were conducted and compared 
to children with T1D only, this phenotype associated nominally with two RGS1 SNPs 
(Table 3 in study IV); rs2816316 (OR 1.88, P=0.006) and rs2984919 (OR 1.82, P=0.008). 
However, the minor allele associated for risk for additional autoimmunity in this analysis 









rs2476601 (PTPN22) and rs4763879 (CD69) associated with having first-degree family 
members with T1D (Table 17). The effect direction for both of these SNPs (minor allele 
predisposing) is the same as reported earlier for T1D and other AIDs. These same SNPs 
were not associated with having first- and/or second-degree relatives with T1D, however. 
Instead, the minor allele for TNFAIP3 associated with risk of familial T1D. This is risk 
allele for other AIDs, but the risk allele for T1D is not known (Table 1 in study IV). SNP 
rs11711054 (CCR3-CCR5) associated with coming from an autoimmune family (OR 
0.69, Table 3 in study IV). Correcting for multiple tests by the FDR procedure removed 
statistical significance from all these findings. 
Multivariate analyses 
A model including DR4-DQ8 was better at explaining multiple AIDs in children with 
T1D compared to the model with only confounding factors (Table 4 in study IV). On the 
contrary, the HLA haplotypes were determined unuseful in explaining clustering in 
autoimmune families. Non-HLA SNPs, however, improved the models for both 
phenotypes in comparison to models including only confounding factors (Table 5 in study 
IV). The SNPs associated with having multiple AIDs were neuropilin 1 (NRP1, 
rs2666236), RGS1 (rs2816316), CD69 (rs4763879), and FUT2 (601338). The SNP 
associated with autoimmune families was CCR3-CCR5 region (rs11711054). 
Effects of combined number of risk alleles 
Combined numbers of risk alleles (0, 1, or 2 per SNP) were compared between the 
phenotypes. For familial T1D, 19 SNPs associated with T1D earlier in the same 
population were included (number of risk alleles weighted by their OR for T1D was also 
used). For phenotype of clustered AIDs other than T1D, the figure was 25 SNPs known 
to be associated with other AID from literature. For autoimmune families, a combination 
of 28 risk SNPs for T1D and other AIDs were calculated. None of these mean/median 
numbers of risk alleles differed between any of the phenotypes (Supplemental Figure 1 










Table 17. Results of association analyses for 41 SNPs in familial T1D compared to 
children with T1D only and without any family history for AIDs. Odds ratios (OR) with 














FDR  P 
value
1 rs630115 LOC646538 A/G 0.33 0.95 0.76-1.19 0.67 0.97 0.81-1.17 0.77
1 rs2476601 PTPN22 A/G 0.22 1.30 1.01-1.66 0.04 0.49 1.15 0.94-1.41 0.18
1 rs2816316 RGS1 G/T 0.13 0.91 0.65-1.26 0.56 0.86 0.66-1.12 0.27
1 rs2984919 RGS1 A/T 0.13 0.94 0.68-1.29 0.69 0.87 0.67-1.13 0.28
1 rs12061474 PIK3C2B T/C 0.19 1.25 0.96-1.61 0.10 1.15 0.93-1.42 0.21
1 rs3024505 IL10 T/C 0.14 0.87 0.63-1.21 0.41 0.84 0.65-1.09 0.20
2 rs6546909 DQX1 T/A 0.16 0.98 0.74-1.30 0.91 0.81 0.64-1.03 0.08
2 rs9653442 LOC150577 C/T 0.45 1.03 0.84-1.28 0.76 1.03 0.86-1.22 0.78
2 rs917997 IL18RAP A/G 0.18 1.02 0.78-1.34 0.87 1.03 0.83-1.29 0.77
2 rs2111485 IFIH1 A/G 0.38 1.03 0.83-1.28 0.81 1.07 0.90-1.27 0.47
2 rs1990760 IFIH1 C/T 0.37 1.01 0.82-1.26 0.90 1.01 0.85-1.21 0.90
2 rs7574865 STAT4 T/G 0.24 1.12 0.87-1.44 0.37 1.08 0.88-1.32 0.47
2 rs3087243 CTLA4 A/G 0.31 0.90 0.71-1.14 0.39 0.91 0.76-1.10 0.35
2 rs11571297 CTLA4 G/A 0.34 0.91 0.73-1.14 0.42 0.93 0.78-1.12 0.45
3 rs11711054 CCR3-CCR5 G/A 0.29 0.88 0.69-1.11 0.28 0.86 0.71-1.05 0.13
3 rs333 CCR5-Delta32 delet. T/A 0.13 1.08 0.79-1.47 0.63 1.13 0.88-1.45 0.33
4 rs17388568 ADAD1 A/G 0.42 0.98 0.79-1.22 0.87 0.89 0.75-1.06 0.20
5 rs7719828 LOC645261 T/C 0.29 1.01 0.80-1.28 0.91 1.01 0.84-1.22 0.88
6 rs3757247 BACH2 A/G 0.38 0.98 0.79-1.22 0.87 0.98 0.82-1.17 0.83
6 rs6920220 TNFAIP3 A/G 0.21 1.28 0.99-1.65 0.06 1.26 1.02-1.55 0.03 0.95
10 rs12722495 IL2RA G/A 0.05 0.99 0.62-1.59 0.97 1.00 0.69-1.46 0.99
10 rs2104286 IL2RA G/A 0.19 0.97 0.74-1.26 0.80 0.92 0.74-1.15 0.48
10 rs4749955 IL2RA C/T 0.46 0.97 0.78-1.20 0.74 1.03 0.87-1.23 0.70
10 rs11258747 PRKCQ T/G 0.27 1.02 0.80-1.30 0.88 0.95 0.79-1.16 0.64
10 rs2666236 NRP1 T/C 0.38 1.07 0.86-1.33 0.56 0.97 0.81-1.16 0.77
11 rs689 INS T/A 0.12 0.78 0.54-1.12 0.17 0.97 0.74-1.27 0.81
12 rs3764021 CLEC2D G/A 0.48 1.23 0.99-1.52 0.06 1.15 0.97-1.36 0.12
12 rs4763879 CD69 A/G 0.36 1.26 1.01-1.57 0.04 0.49 1.17 0.98-1.39 0.09
12 rs1701704 IKZF4 C/A 0.37 1.04 0.83-1.29 0.76 1.00 0.84-1.19 0.98
12 rs4646536 CYP27B1 C/T 0.34 0.95 0.76-1.19 0.64 1.01 0.84-1.21 0.90
12 rs2292239 ERBB3 A/C 0.34 1.10 0.87-1.37 0.43 1.03 0.86-1.24 0.75
12 rs3184504 SH2B3 T/C 0.44 0.90 0.72-1.12 0.33 0.96 0.81-1.14 0.66
12 rs17696736 C12orf30=NAA25 G/A 0.42 0.94 0.75-1.17 0.57 0.92 0.77-1.10 0.39
13 rs9585056 GPR183 C/T 0.26 1.04 0.81-1.32 0.78 0.99 0.82-1.21 0.96
15 rs3825932 CTSH T/C 0.37 1.12 0.90-1.39 0.31 1.02 0.86-1.22 0.83
16 rs12708716 CLEC16A G/A 0.30 0.97 0.77-1.23 0.83 1.03 0.85-1.24 0.75
16 rs2903692 CLEC16A A/G 0.28 0.94 0.74-1.20 0.62 0.99 0.82-1.20 0.91
18 rs45450798 PTPN2 C/G 0.18 1.06 0.81-1.39 0.67 1.00 0.80-1.25 0.99
18 rs763361 CD226 T/C 0.46 1.02 0.82-1.26 0.86 1.05 0.88-1.25 0.58
19 rs601338 FUT2 A/G 0.40 1.24 1.00-1.54 0.05 0.49 1.10 0.92-1.31 0.30
19 rs602662 FUT2 A/G 0.44 1.21 0.98-1.50 0.078 1.08 0.91-1.28 0.39
T1D in first-degree relatives 
(n=221)










This study aimed at collecting current data on frequencies of additional autoimmunity in 
children with newly diagnosed T1D and in their relatives, characterizing the diabetes 
phenotype of these children according to their autoimmune history for AIDs in general 
and for CD specifically, as well as delineating the effect of non-HLA genes on clustering 
autoimmunity. At least 3.2% of the children with T1D developed additional AIDs, 23% 
reported first- and/or second-degree relatives with T1D, and over a third, relatives with 
other AIDs. Differencies especially in genetic etiology were discovered behind different 
phenotypes of clustering autoimmunity  
Frequency of AIDs in T1D 
Our results are in line with the notion that most additional AIDs develop after the 
diagnosis of T1D; only 1.6% of the children had another AID at diagnosis whereas a 
prevalence of 3.2% was calculated later even without systematic follow-up for all the 
children. These figures are in accord with those reported previously in the literature, 
although lower than reports that have systematically screened for different autoantibodies 
or included longer follow-up. In accordance with previous reports, CD and AIT were the 
most prevalent conditions. For other AIDs the figures presented in the thesis are based 
on self-reporting of known diagnoses, but CD was screened by anti-tTG. The prevalence 
of celiac disease among systematically screened children with T1D in our study was 3.2% 
(1.5% of the total cohort of 2245 children), which is close to the median 4% found in 
literature reviews [197, 198, 273]. The variation between populations is wide, however, 
and for example in the neighboring Sweden the prevalence of CD among T1D patients is 
10% [182, 229]. In general, the prevalence of the high CD risk haplotype, DR3-DQ2, 
among Finnish patients with T1D is relatively low; the prevalence of this haplotype was 
35.3% in our study compared to 50-60% reported in other populations [52, 274-276]. 
The frequency of familial T1D was 23%; 13.6% in first-degree and 12.5% in second-
degree relatives. The proportion of familial T1D has remained similar from the 1990’s 
when Veijola et al. reported the prevalence of first-degree familial T1D of 15.1% [145]. 
More than a third of the children reported extended family members with AIDs other than 
T1D, which is in accordance with previous literature. As expected these diseases were 
more commonly reported in second-degree relatives, who are generally older and thus 
more susceptible to most AIDs, for example rheumatoid diseases. Accordingly, AIT and 









In study III, the prevalence of CD in the first-degree relatives (2.4%) was the same 
as that reported for Finnish adult general population [227], suggesting that the risk of CD 
is might not be elevated in first-degree relatives of Finnish children with type 1 diabetes. 
Similar reports have been published earlier with siblings of Finnish T1D patients [277].  
Gender differences 
Some interesting gender differences were evident. In general, T1D is an exceptional AID 
since there is no excess of female patients. Additionally, there are peculiar gender 
differences in the inheritance of the disease; T1D is more common in fathers than in 
mothers, and accordingly our prevalence in fathers (6%) was double that in mothers (3%). 
In epidemiological studies of T1D, preferential transmission from fathers to daughters 
and from mothers to sons has been reported, although our results do not support this. In 
contrast, our data supports a similar phenomenon from grandparents to grandchildren; 
maternal grandparents transmitted the disease to boys and paternal grandparents to girls. 
There were differences in HLA genetics to support this finding as well, although the 
actual mechanism for this phenomenon remains unknown. Interestingly, similar gender 
patterns have been described in MS, which is more prevalent in females, and the risk of 
the offspring, especially daughters, is higher for affected mothers. In fact, the risk 
mediating HLA-DRB1*15 has been shown to be preferentially transmitted from mothers 
[278, 279]. In female patients, the risk is additionally influenced by gender of affected 
second-degree relative (aunt-uncle). Also, the risk carried by HLA-DRB1*15 is 
significantly greater in families with affected second-degree relatives compared to 
families with only affected first-degree relatives. Suggested reasons behind these changes 
are gene-environment interactions and epigenetic changes [215].  
Despite fathers having T1D more often than mothers, affected maternal and paternal 
second-degree relatives were reported equally often, as were affected grandfathers and 
grandmothers. In contrast, for AIDs other than T1D, mothers were more often affected 
than fathers, which is in line with autoimmunity associating with female gender in 
general. In keeping with this, affected maternal second-degree relatives were reported 
more often than paternal second-degree relatives. As these relatives are of both sexes, i.e. 
maternal grandfathers and uncles in addition to grandmothers and aunts, this difference 
cannot be attributed to gender. The difference could arise from recollection bias as 
mothers may be more aware of the diseases of their family members. Furthermore, 
mothers might be the primary parent accompanying the child to the diabetes visits and be 
the parent responsible for filling out the questionnaire for the Register. Such a 









relatives, but this was not evident in this dataset. Other possibility is that AIDs are 
preferentially transmitted from the maternal side of the family by some unknown 
mechanism. Interestingly, this has been described in MS, with the disease being 
preferentially transmitted to offspring from maternal compared to paternal aunts/uncles 
[280]. Reasons for such pattern of transmission are unknown. 
As AIDs are usually more common among females, more girls with an additional 
AID in combination with T1D could have been expected. Indeed, a tendency for this was 
evident with 4.0% of girls and 2.6% of boys having additional AIDs, but the difference 
did not reach statistical significance (P=0.09) possibly due to inadequate power. Study 
III focused on CD, and a unique gender distribution was discovered; contrary to the usual 
female predominance in CD, both sexes were equally often affected. Among the first-
degree relatives there was the usual female majority, however. 
Characterizing type 1 diabetes associated with clustered autoimmunity 
We hypothesized that the children with clustered autoimmunity would form a separate 
subgroup in terms of their diabetes phenotype and genotype. We assumed that genetic 
risk for autoimmunity would be higher in families with clustered AID, i.e. gene regions 
known to be associated with a broad spectrum of autoimmune disorders (e.g. HLA-DR3-
DQ2, PTPN22, CTLA-4) were expected to be overrepresented. We also expected a 
broader humoral autoimmune reaction in children with wide range of autoimmune 
phenotypes.  
The differences evident in humoral autoimmune profile were the opposite from our 
hypothesis, however. More specifically, children with familial T1D, children from 
autoimmune families, and children with additional AIDs (other than CD) were less often 
positive for ICA. Results in the same direction (lower frequency of autoantibody 
positivity) were seen for children with additional AIDs for IA-2A and ZnT8A. Moreover, 
these children, especially children who already had or later developed CD, had a lower 
number of positive islet autoantibody responses at diagnosis of T1D. These differences 
might be due to differential genetic background. For children with T1D and CD, the 
differences are readily explained by the high prevalence of DR3-DQ2 haplotype. DR3-
DQ2 has been associated mostly with GADA and low/less prevalent IAA and IA-2A [20, 
24]. ICA are associated with DR4-DQ8 [20] and thus a higher, not lower as observed, 
prevalence could have been expected in familial T1D. Consequently, these findings are 
difficult to explain. Some significant P values could also arise by chance. Nevertheless, 
as GADA are associated to general propensity to autoimmunity, an increased prevalence 









high GADA levels were seen in children with multiple AIDs in study II after adjustement 
for age at T1D onset (Table 1 in Study II). Also, relatives positive for anti-tTG in study 
III had GADA more often. In the pooled results, however, differences in GADA 
prevalences or titers did not reach statistical significance.  
Familial T1D was characterized by better clinical situation at diagnosis of T1D even 
when the affected relatives were second-degree relatives. In Finland, these relatives 
usually do not live in the same household as the immediate family. These results are 
encouraging in the sense that the information of the disease seems to spread even from 
relatives outside the immediate family allowing earlier recognition of the disease. As the 
prevalence of the sporadic disease was less than 80% when second-degree relatives were 
considered, the finding is promising in terms of attempts to prevent diabetic ketoacidosis. 
On the other hand, the prevalences of ketoacidosis (10% of first-degree familial cases 
and 11% of second-degree familial cases) are still high and there is room for improvement 
of early recognition of T1D.  
Having family members with AIDs other than T1D did not affect the markers of the 
metabolic decompensation at diagnosis. However, if the child had an AID diagnosed 
already before diagnosis of T1D (study II), the clinical situation was better than children 
with T1D alone. Perhaps these children are being followed-up for their disease and are 
therefore screened or their symptoms are recognized earlier than for children without 
such diseases. However, the duration of symptoms was in fact longer, not shorter, 
contradicting the idea of earlier diagnosis behind the milder metabolic decompensation. 
One possible explanation would be recollection bias; it is possible that families with prior 
experience of AIDs think that they should have been able to recognize the very early 
symptoms and accordingly estimate longer duration of symptoms than sporadic cases. It 
is also possible that the pathogenesis of T1D is different in these children and perhaps 
the course of development of T1D is slower or milder leading to less symptoms at 
diagnosis, although our data does not support this. If the children diagnosed with 
additional AIDs later during follow-up were included in the analysis, the differences in 
markers of metabolic decompensation were less pronounced. This finding would support 
the hypothesis of children with pre-existing conditions being more closely monitored for 
additional diseases or that the possible slower disease progression is limited to children 
diagnosed with additional AIDs before T1D diagnosis. 
We hypothesized that children with additional AIDs or family history for such 
diseases would have an increased HLA mediated risk. For familial T1D this has been 
described in Finnish population as higher prevalences of risk genotypes DR3-DQ2/DR4-









protective genotypes among children with first-degree relatives with T1D [145]. In study 
I, with information on family history of T1D limited only to the situation at diagnosis of 
the index case, we saw differences only in one haplotype; HLA-DR4-DQ8. However, 
with a larger sample size, data on additional T1D diagnoses in the family, and with a 
different comparison group more differences became apparent; children with familial 
T1D had more often one or two copies of the DR4-DQ8 haplotype and less often a 
genotype without either of the risk haplotypes. Children with family history of AIDs other 
than T1D or children from autoimmune families did not differ in terms of HLA class II 
genetics, but family history of CD associated with DR3-DQ2 in the index child.  
Children with additional AIDs differed in their HLA genetic profile; children with 
CD related autoimmunity had the DR3-DQ2 haplotype or related genotypes whereas 
children with AIDs other than CD had more often genotypes without either of the T1D 
risk haplotypes or genotypes protective for T1D. Accordingly, it seems that children with 
multiple AIDs are prone to develop T1D with weaker HLA-mediated risk and even with 
HLA-mediated protective genotypes. This provokes interesting questions about the 
pathogenesis of T1D in these children. They might have some other genetic loci 
predisposing them to T1D or autoimmunity in general, or some strong environmental 
factors leading to break-up of self-tolerance. Possibly the loss of tolerance is first 
developed against other tissues and later spread to β-cells. In study IV, RGS1 was 
associated with other AIDs in children with T1D. Half of this group of children had CD, 
however, and this could account for the association, as RGS1 is a known CD risk SNP 
[86].  Nevertheless, this group of children with AIDs other than CD is an interesting 
group for further studies on clustering autoimmunity.  
Together, these results indicate that HLA class II genetics plays a role in familial 
clustering of T1D and CD; HLA-DR4-DQ8 in familial T1D and DR3-DQ2 in T1D with 
CD autoimmunity. Differential disease pathways have been suggested for these 
haplotypes; DR4-DQ8 associates with IAA and DR3-DQ2 with GADA as the first 
autoantibody [25-27]. Accordingly, familial T1D could arise throught the pathogenetic 
route of IAA and T1D in the context of CD through GADA. We can not analyse this 
directly, however, as the Register does not include data from the prediabetic period. 
The differences in HLA genotype/haplotype profiles for familial T1D were modest 
with a sample size of 324 in study I, whereas at the end of study with a sample of 522 
familial T1D cases, more differences could be seen. In 1996, the differences in HLA class 
II genetics were evident already with a sample size of 121 familial cases and the 
prevalence of the highest risk HLA class II genotype DR4-DQ8/DR3-DQ2 among 









the other haplotypes and genotypes is difficult since the risk grouping of HLA class II 
genetics has changed. This decrease in the prevalence of high risk genotype may indicate 
that the effect size of HLA class II genetics on familial clustering has decreased within 
the last decades with more pressure for this clustering from environmental risk factors. 
Similar phenomenon has been seen in T1D development; patients diagnosed with T1D 
recently have a lower HLA mediated genetic risk for T1D than patients diagnosed 
decades ago, suggesting that the need for genetic susceptibily to develop the disease has 
decreased as the environmental pressure for disease development has increased [281]. 
As multiple other genetic loci have been associated with AIDs in addition to HLA, 
we tested the involvement of these in clustering of autoimmunity. However, the power 
of the study was very limited and thus convincing results were difficult to acquire. 
Multivariate analysis, however, indicated an overall effect of non-HLA SNPs on 
clustering of AIDs in children with multiple AIDs and in autoimmune families. Some 
candidate genes were discovered, but need validation in other studies. RGS1 and CCR2-
CCR5 alleles predisposing to T1D seemed to protect from clustering autoimmunity, 
which could just reflect a decreased genetic risk load to T1D in clustered autoimmunity. 
Nevertheless, PTPN22 as a risk gene for familial T1D is a credible finding as this is a 
gene with relatively large effect size on T1D and has a function in immune reactions. 
However, the association was only seen in children with first-degree relatives with T1D, 
not if affected second-degree relatives were included. Interestingly, no association with 
INS was evident although this is a strong risk SNP and unique for T1D. Nonetheless, it 
is important to keep in mind, that despite the limited power of the study, large effect sizes 
of these SNPs on clustering of AIDs would have been discovered. Our findings are in 
line with the notion that the genetic predisposition to familial T1D is mainly attributed to 
HLA class II genes and not genes outside the HLA region [74], as observed by smaller 
effect sizes for non-HLA loci in families with affected siblings than from sporadic cases 
[66]. Additionally, these results emphasize the role of other factors in clustering of 
autoimmunity. Indeed, environmental risk factors cluster in families in addition to genetic 
factors, and can thus explain the increased risk in family members compared to general 
population. Shared microbiota, intrafamilial spread of enteroviruses [282], and nutrition 
are examples of suggested T1D risk factors that are shared by family members.  
We observed differences in the family demographics between different phenotypes 
of clustered autoimmunity. These are mostly direct results of the definitions used. For 
example the children with positive family history for AID other than T1D and the 
children from autoimmune families came from larger families, since in larger families 









were the only child of the family were younger at diagnosis since families with very 
young children have not had the time to have more children. 
Transient anti-tTG at diagnosis of T1D? 
Children with both T1D and CD had some unique features compared to children with 
only one of the diseases. These children had the HLA class II haplotype DR3-DQ2 more 
often than children with T1D only (79% vs. 36%) and less often than usually reported for 
children with CD (90%). They had a lower number of islet cell autoantibodies. This could 
be due to the difference in HLA DR3-DQ2 prevalence, or a different – perhaps less 
aggressive – β-cell destruction in children with ongoing celiac autoimmunity or in those 
who will develop this autoimmunity later. Also, both boys and girls with T1D equally 
often developed CD in contrast to the usual female predominance evident both in children 
and adults with CD only.  
There was a striking difference between index children and first-degree relatives in 
the proportion of those who were anti-tTG positive in the Register sample and were 
diagnosed with CD; only 36% of the index children and 60% of the relatives positive for 
anti-tTG had CD. The index children did not have lower levels of anti-tTG, but they were 
less often positive for EMA. It is possible that some of these children will develop CD in 
the future, although information from the hospitals in charge of the follow-up indicated 
that most of these children were negative for CD related autoantibodies during follow-
up. First-degree relatives of these children were also older and might therefore have 
developed CD more often. Also, they might have developed CD autoimmunity long 
before the sample was taken and suffered from silent CD. Nevertheless, these factors do 
not fully explain why children with newly diagnosed T1D were anti-tTG positive so often 
but still did not develop CD. A plausible explanation would be transient anti-tTG 
positivity related to the time of diagnosis of T1D in the index children. There are previous 
reports of transient anti-tTG positivity in 50% of children without T1D but genetically at 
risk for CD [283] and false positives in anti-tTG testing are generally described more 
often in patients with other AIDs [200]. In a prospective Italian study from T1D diagnosis 
onwards, 40% of those positive for anti-tTG showed fluctuating levels during follow-up 
and 28% became negative. The normalization of anti-tTG was associated with being 
EMA negative, low levels of anti-tTG, being asymptomatic, and older age at CD 
autoantibody development [258]. In Israel, spontaneous normalization of anti-tTG 
occurred in 35% of pediatric T1D patients [242], and the authors proposed a 12-month 
serological follow-up of cases with low anti-tTG levels before biopsy. In other reports 









237, 284]. The proposed mechanisms of transient autoantibodies have been associated 
with active β-cell destruction [247] or abnormal immunoglobulin levels (elevated IgA) 
[237, 285] at diagnosis of T1D. Studies with systematic screening of CD related 
autoantibodies around the time of diagnosis of T1D should be carried out to clarify 
whether this time is especially vulnerable to transient autoimmunity. 
Strengths and limitations of the study 
This study is a relatively large population-based observation study of children diagnosed 
with T1D in a country of highest incidence for this disease in the world. Accordingly, the 
Finnish population is especially interesting for the study of diabetes and we had a unique 
resource in the Finnish Pediatric Diabetes Register with its coverage of over 90% of all 
children diagnosed with T1D in the country since 2002. We were, however, forced to use 
only the children who participated in the Sample Repository in our studies, since we 
wanted to compare genetics and humoral autoimmunity profiles. This might cause some 
selection bias, since there seemed to be a tendency for children with family history of 
T1D to provide samples in addition to the Register questionnaire more frequently. It is 
reasonable to assume, that families who have many members with T1D or other AIDs, 
might be more motivated to participate in studies of these diseases compared to children 
without such a family history. This bias might somewhat overestimate our figures of 
clustering autoimmunity, but systematic bias in comparison of familial and sporadic cases 
seems unlikely. Moreover, our study was completely unable to aquire data on those who 
did not participate in the Register at all. 
In addition, in ascertaining the autoimmune diagnosis of the children and their family 
members were relied on information provided by the families on a questionnaire. A more 
reliable way of ascertainment would have been to screen for autoantibodies for different 
diseases, or ascertainment from patient records or national registers. These methods 
would have been too costly and laborsome and, accordingly, would have limited the 
sample size. It is likely that there is both under- and overreporting of AIDs in the 
questionnaire although help of diabetes nurse or doctor was encouraged in the filling of 
the questionnaire. Thus, we cannot guarantee the autoimmune origin of all diagnoses 
reported. However, these shortcomings should not lead to any systematic bias in either 
direction as both under and overreporting are expected. Not all families want to disclose 
all information on the family in the questionnaire. As a result, not all siblings and diseases 
of the relatives are reported. Also, detailed information on missing information of AIDs 









in the questionnaire represented cases without AIDs. Thus, our figures on frequencies of 
having AIDs in relatives might be slight underestimations.  
The Register is a cross-sectional study without systematic follow-up of the children. 
Thus, most information included in the study is from a single time-point. We have no 
information from the preclinical phase of T1D development, and thus cannot study for 
example the temporal development of islet autoantibodies. The follow-up data for CD 
and AIT is acquired by alternative follow-up methods and only for a subset of the 
families. Therefore, the prevalences of AIDs reported are underestimations, and CD and 
AIT are overrepresented in relation to other AIDs. However, compared to original 
studies, increasing the sample size and adding all the available follow-up data for the 
pooled analysis, increased the power of the study to detect differences between familial 
and sporadic cases (i.e. additional genetic differences in familial T1D described here 
compared to study I). These limitations in ascertainment of cases with AIDs might dilute 
the differences detectable between cases with and without addional autoimmunity.  
In studies on non-HLA genetics, the small sample size leading to inadequate power 
was the major limitation. Despite being based on a large nationwide register, the numbers 
of cases in the phenotype groups are not large enough, which emphasizes the need for 
large international studies. In addition, the SNPs used in the analyses were primarily 
chosen for analysis for T1D risk association. The comparisons of phenotypes of 
clustering of other AIDs might have required a different set of SNPs. Accordingly, our 










1. At diagnosis of T1D, 1.6% of Finnish children have additional AIDs. This 
proportion increases to at least 3.2% after median of eight years of follow-up. 
The children with CD and T1D carry the HLA-DR3-DQ2 haplotype, while 
children with AIDs other than CD carry neutral or protective T1D HLA-
genotypes conspicuously often. Also, non-HLA loci contribute to the clustering 
of AIDs, and RGS1 (rs2816316) is a candidate gene in children with multiple 
AIDs. These children have some differences in islet autoantibodies, possibly due 
to the differences in HLA class II genetics. The duration of T1D symptoms is 
longer for children with additional AIDs, and additional evidence suggests 
milder onset of T1D in such children. 
 
2. More than 20% of children with recent-onset T1D in Finland come from 
extended families with T1D. Affected first- and second-degree relatives are 
reported equally often (~12%), whereas fathers are affected twice as frequently 
as mothers (6 vs. 3%). Girls have paternal and boys maternal second-degree 
relatives affected by T1D more often. Familial T1D is characterized by an 
increased prevalence of the HLA-DR4-DQ8 haplotype but differences in islet 
autoantibodies are modest. Increased awareness of the disease in the extended 
family – even if only second-degree relatives are affected – leads to a 
significantly better metabolic status at diagnosis. 
 
3.  Over a third of children with T1D in Finland have extended family members 
with AIDs other than T1D. Mothers are affected more than twice as often as 
fathers (10 vs. 4%). Children with extended family history for other AIDs come 
from larger families, but differences in HLA class II genetics, islet autoantibodies 
or metabolic decompensation at diagnosis are only modest. Non-HLA loci, in 
contrast, contribute to this autoimmune clustering, and rs11711054 (CCR3-
CCR5) is a candidate gene for familial autoimmunity. 
 
4. According to systematic screening data of Study III, of the Finnish index children 
with newly diagnosed T1D, 5% have anti-tTG and of their relatives 3%. The 
prevalence of CD was 3.2% for index children (1.5% for the total cohort of 2245) 









more often female. HLA-DR3-DQ2 is related to CD autoimmunity in index 
children and relatives. Transient anti-tTG not developing to CD seems more 
common among children with T1D compared to their first-degree relatives. 
 
In summary, differencies in genetic etiology were discovered behind different 
phenotypes of clustering autoimmunity, but clear-cut associations for e.g. certain islet 
autoantibodies were not evident. Prospective studies with follow-up before and after T1D 
diagnosis would provide data for example on the timing of islet autoimmunity and the 
appearance of additional AIDs, but such studies would require very large cohorts to have 
adequate power. The observed candidate non-HLA associations and transient anti-tTG in 
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